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UK DRAFFT: a randomised controlled trial of percutaneous
fixation with Kirschner wires versus volar locking-plate
fixation in the treatment of adult patients with a dorsally
displaced fracture of the distal radius
Matthew L Costa,1* Juul Achten,2 Caroline Plant,1 Nick R Parsons,2
Amar Rangan,3 Sandy Tubeuf,4 Ge Yu4 and Sarah E Lamb2,5
1Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry and University
Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
2Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
3Wolfson Research Institute for Health and Wellbeing, School of Medicine and Health,
Durham University, Durham, UK
4Leeds Institute of Health Sciences, Leeds University, Leeds, UK
5Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology &
Musculoskeletal Sciences, University of Oxford, Oxford, UK
*Corresponding author Matthew.Costa@warwick.ac.uk
Background: In high-income countries, 6% of all women will have sustained a fracture of the wrist
(distal radius) by the age of 80 years and 9% by the age of 90 years. Advances in orthopaedic surgery
have improved the outcome for patients: many such fractures can be treated in a plaster cast alone, but
others require surgical fixation to hold the bone in place while they heal. The existing evidence suggests
that modern locking-plate fixation provides improved functional outcomes, but costs more than traditional
wire fixation.
Methods: In this multicentre trial, we randomly assigned 461 adult patients having surgery for an
acute dorsally displaced fracture of the distal radius to either percutaneous Kirschner-wire fixation or
locking-plate fixation. The primary outcome measure was the Patient-Rated Wrist Evaluation© (PRWE)
questionnaire at 12 months after the fracture. In this surgical trial, neither the patients nor the surgeons
could be blind to the intervention. We also collected information on complications and combined costs
and quality-adjusted life-years (QALYs) to assess cost-effectiveness.
Results: The baseline characteristics of the two groups were well balanced and over 90% of patients
completed follow-up. Both groups of patients recovered wrist function by 12 months. There was
no clinically relevant difference in the PRWE questionnaire score at 3 months, 6 months or 12 months
[difference at 12 months: –1.3; 95% confidence interval (CI) –4.5 to 1.8; p= 0.398]. There was no
difference in the number of complications in each group and small differences in QALY gains (0.008;
95% CI –0.001 to 0.018); Kirschner-wire fixation represents a cost-saving intervention (–£727; 95% CI –£588
to –£865), particularly in younger patients.
Conclusions: Contrary to the existing literature, and against the increasing use of locking-plate fixation,
this trial shows that there is no difference between Kirschner wires and volar locking plates for patients
with dorsally displaced fractures of the distal radius. A Kirschner-wire fixation is less expensive and quicker
to perform.
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Trial registration: Current Controlled Trials ISRCTN31379280.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 19, No. 17. See the NIHR Journals Library website
for further project information.
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Plain English summary
In high-income countries, 6% of all women will have sustained a fracture of the wrist (distal radius) bythe age of 80 years and 9% by the age of 90 years. Advances in orthopaedic surgery have improved the
outcome for patients; many such fractures can be treated in a plaster cast alone, but others require
surgical fixation to hold the bone in place while they heal. The existing evidence suggests that a modern
‘locking-plate’ fixation provides improved wrist function but costs more than traditional ‘wire’ fixation.
In this study, we randomly assigned 461 adult patients having surgery for a fracture of the distal radius to
either Kirschner-wire (K-wire) fixation or locking-plate fixation. The patients reported their own outcome
in the 12 months after their fracture, using the Patient-Rated Wrist Evaluation. We also collected
information on complications and costs.
Over 90% of the patients who took part completed the study. Both groups of patients recovered wrist
function by 12 months, although their wrists were not quite back to normal. There was no difference in
their wrist function at 3 months, 6 months or 12 months. Nor was there a difference in the number of
complications in each group. K-wire fixation is ‘cost saving’, particularly in younger patients.
Contrary to the existing literature, and against the increasing use of locking-plate fixation, this study shows
that there is no difference between K-wires and locking plates for patients with fractures of the distal
radius. K-wire fixation is less expensive and quicker to perform.
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Scientific summary
Background
Fractures of the distal radius are extremely common injuries. In high-income countries, 6% of women will
have sustained such a fracture by the age of 80 years and 9% by the age of 90 years. All age groups are
affected; younger patients frequently sustain complicated, high-energy injuries involving the wrist joint
but fractures of the distal radius are also common in older patients, who are more likely to sustain
low-energy fractures, related to osteoporosis.
Fractures of the distal radius are treated non-operatively if the bone fragments can be held in anatomical
alignment (reduction) by a plaster cast or orthotic. However, if this is not possible then surgical fixation
is performed. This carries inherent risks for the patient and considerable cost implications; much of this
cost is related to the choice of fixation.
The two most common forms of surgical fixation are percutaneous Kirschner-wire (K-wire) fixation and
locking-plate fixation.
Kirschner-wire fixation is a long-standing technique in which smooth metal wires with a sharp point are
passed across the fracture site through the skin. However, this technique is rapidly being superseded by
locking-plate fixation, in which a plate is attached to the bone with fixed-angle screws. To date, studies
comparing K-wire fixation and volar locking-plate fixation have indicated that locking plates provide
improved radiological and/or functional outcomes.
In this multicentre randomised trial, the Distal Radius Acute Fracture Fixation Trial (DRAFFT), we compared
K-wire fixation with locking-plate fixation for patients with a dorsally displaced fracture of the distal radius.
Methods
Patients
We enrolled patients from 18 centres in the UK.
Patients were aged ≥ 18 years with a dorsally displaced fracture of the distal radius within 3 cm of the
radiocarpal joint. The other inclusion criteria were that the treating surgeon believed that the patient
would benefit from surgical fixation of the fracture and that the injury was < 2 weeks old.
Patients were excluded if the fracture extended > 3 cm from the radiocarpal joint, if the fracture was open
(with a Gustilo grading greater than 1), if the articular surface of the radiocarpal joint could not be
reduced by indirect techniques (in some fractures, the joint surface is so badly disrupted that the surgeon
will have to open up the fracture in order to restore the anatomy under direct vision), if there was a
contra-indication to anaesthesia or if the patient was unable to complete questionnaires.
Measures
Patient characteristics and baseline (pre-injury) functional status were self-reported after consent to take
part in the trial. The primary outcome measure was the validated Patient-Rated Wrist Evaluation© (PRWE)
questionnaire. The secondary outcome measures were the Disabilities of Arm, Shoulder and Hand
(DASH) questionnaire score, the EuroQol – Five Dimensions (EQ-5D), complications related to the surgery
and resource use. The primary and secondary measures were collected by postal questionnaire at baseline,
3, 6 and 12 months after surgery.
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xxi
Study treatments
All of the hospitals and the surgeons involved in the trial were familiar with both fixation techniques.
Although the basic principles of percutaneous K-wire fixation and locking-plate fixation are inherent in the
design of the implants, the details of the surgery were left to the discretion of the surgeon to ensure that
the results of the trial could be generalised to as wide a group of patients as possible.
Kirschner-wire fixation: the wires are passed through the skin over the dorsal aspect of the distal radius
and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number
of wires, the insertion technique and the configuration of wires were decided by the surgeon. A plaster
cast was applied to supplement the wire fixation as per usual surgical practice.
Locking-plate fixation: the locking plate is applied through an incision over the volar (palm) aspect of the
wrist. The details of the surgical approach, the type of plate, and the number and configuration of
screws were decided by the surgeon. The only stipulation was that the screws in the distal portion of the
bone were ‘fixed-angle’, that is screwed into the plate, but this is standard technique for the use of these
plates. Some surgeons use a temporary plaster cast after the procedure, but the fixed-angle stability
provided by the locking plate is generally sufficient to allow early controlled range-of-movement exercises.
Rehabilitation: all patients received the same standardised written physiotherapy advice. Those patients
in the K-wire group were encouraged to perform range-of-movement exercises at the wrist as soon
as their plaster cast was removed. Those patients in the locking-plate group were encouraged to begin the
exercises immediately if they did not have a plaster cast, or as soon as the cast was removed.
Randomisation
Following informed consent, the method of fixation was allocated using a secure, centralised telephone
randomisation service. The randomisation sequence was generated and administered at an independent
clinical trials unit (York, UK) to ensure that allocation was concealed. Randomisation was on a 1 : 1 basis,
stratified by centre, intra-articular extension of the fracture and age of the patient.
Stratification by centre ensured that any clustering effect related to the centre itself was equally distributed
in the trial arms. Stratification on the basis of intra-articular extension of the fracture (specifically
involvement of the articular surface of the radiocarpal joint) eliminated a major potential confounder,
since disruption of this articular surface may predispose to secondary osteoarthritis of the wrist. Stratification
on the basis of age (≥ or< 50 years) was used to balance, between the groups, the number of younger
patients with normal bone quality sustaining high-energy fractures and older patients with low-energy
(fragility) fractures related to osteoporosis. Age was, therefore, used as a surrogate for bone density.
Blinding
The operating surgeon could not be blind in the trial, and, as the K-wires protrude on the back of the
wrist and the locking plate requires an incision, neither could the patient. However, all staff involved in
checking, entering and analysing questionnaire responses were blinded.
Statistical analysis
The PRWE questionnaire score at 12 months was the primary outcome measure. A six-point difference
in the PRWE questionnaire score equates to a standardised effect size of 0.3, for an assumed standard
deviation of 20 points. At the individual level, a change in the PRWE questionnaire score of 6 points
reflects the difference between turning a doorknob with mild pain and no pain.
A six-point difference between groups at the 5% level with 80% power required 175 patients in each
group, that is 350 patients in total. With an allowance for a conservative 10% loss to follow-up,
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we planned to recruit 390 patients. However, as a result of faster than expected recruitment to the trial,
and with the permission of the Review Board, we were able to recruit 461 patients.
Differences between treatment groups were assessed on an intention-to-treat basis, using a normal
approximation for the PRWE questionnaire score, at 3 months, 6 months and 12 months. Pre-planned
subgroup analyses of the PRWE questionnaire scores were based on the stratification by intra-articular
extension and age ≥ or< 50 years. A secondary analysis based on the type of fixation provided
(per-treatment analysis) was also pre-planned. Tests were two-sided and considered to provide evidence
for a significant difference if p-values were less than 0.05 (5% significance level).
The statistical analysis plan was agreed with the independent Data Management Committee at the start of
the study.
Health economic analysis
The economic evaluation was designed to estimate costs of both treatments, and the incremental
cost-effectiveness of distal radial fractures treated by locking-plate fixation versus K-wire fixation. The
primary outcome for the economic evaluation was the number of quality-adjusted life-years (QALYs) gained,
using the EQ-5D. Primary, secondary, community and social care service usage, medications and aid usage
were retrospectively collected using a short patient questionnaire administered at 3, 6 and 12 months
post surgery. Patients also reported out-of-pocket expenditure related to their treatment, lost productivity
and support from personal services.
We compared costs and QALYs, calculated incremental cost-effectiveness ratios (ICERs) and examined the
probability of cost-effectiveness by constructing cost-effectiveness acceptability curves.
Results
Patients
During the recruitment period, 178 potentially eligible patients were unwilling to take part. From
January 2011 to the end of July 2012, 461 patients were randomised. Of the 230 patients assigned to
K-wires, 208 (90%) had the allocated treatment and, of the 231 patients assigned to locking-plate fixation,
213 (92%) were treated as allocated. The baseline characteristics of the two groups were very similar.
Treatments were undertaken by 244 different surgeons; the median number of operations per surgeon
was 1 (interquartile range 1–2). Of note, the surgical time for the K-wire fixation was less than for a
locking plate with a mean difference of 33 minutes [95% confidence interval (CI) 28 to 37, p< 0.001
(t-test)].
Also of note was the greater rate of perioperative antibiotic use in the locking-plate group than the K-wire
group; 83% versus 71% of study participants required antibiotics (estimated odds ratio 3.5, 95% CI 2.0
to 6.5; Fisher’s exact test, p< 0.001).
Primary outcome
Wrist scores improved in the postoperative period in both groups, although function at 12 months was still
approximately 15% worse than before the injury.
There was no evidence of a statistically significant difference in PRWE questionnaire scores between
the treatment groups at any time point. The adjusted estimate of the treatment effect for the PRWE
questionnaire score at 12 months after surgery was –1.3 [95% CI –4.5 to 1.8; p= 0.398; F-test for
treatment factor from model analysis of variance (ANOVA)].
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Patients ≥ 50 years of age formed a sizeable subgroup (74%, 341 out of 461); therefore, this was
identified a priori as being of particular interest. The adjusted estimate of the treatment effect in this age
group was –2.2 (95% CI –5.8 to 1.4) in favour of the plate group; the p-value of 0.338 (F-test from
ANOVA) indicates that there is no evidence of a significant interaction term between age group
and treatment.
Secondary analyses
There was evidence for a marginally significant (p= 0.051) treatment effect in favour of the locking-plate
group for the DASH questionnaire score at 12 months only, although the effect size was small
(–3.2; 95% CI –6.5 to 0.0). EQ-5D did not show any significant differences between treatment groups.
The per-treatment analysis (according to the fixation performed) for PRWE questionnaire scores gave an
adjusted treatment effect estimate of –1.0 (95% CI –4.2 to 2.2; p= 0.530).
There are 46 study participants with missing primary outcome data at the 12-month study end point;
the data are 90.0% (415/461) complete. The inferences based on the complete data, after imputation,
were not markedly different from those reported from the complete case analysis.
There was no evidence to suggest that rates of any complications differed between study groups,
based on comparing counts in groups. As expected, more patients were given a cast after the operation
in the K-wire group, and subsequently that group had a greater number of plaster changes.
Resource use
The mean cost associated with the surgical fixation of the fracture was higher in the locking-plate group:
£818 for the locking-plate fixation and consumables versus £54 for the K-wires and consumables.
Total NHS costs were significantly higher, £903, in the locking-plate group and consumables (95% CI 393
to 1414; p< 0.001) and societal costs were marginally higher, £45, in the K-wires and consumables group.
The incremental cost-effectiveness ratios of volar locking-plate fixation compared with K-wire fixation were
always more than £30,000 per QALY.
Probabilities of the cost-effectiveness of volar locking plates at a willingness to pay £20,000 per QALY
are near nil in both perspectives for all patients. The results indicate that effectiveness, as measured in
QALYs, differs with patients’ age group. In the subgroup of older patients, cost-effectiveness peaks at 46%
in the NHS perspective and 48% in the societal perspective. However, in patients aged < 50 years,
K-wire fixation always dominates (more gain at cheaper cost).
Discussion
Despite the expense associated with locking-plate fixation of distal radius fractures, millions of patients
have been treated with locking plates around the world. In this trial, we have shown that locking plates
offer no advantage over the older and cheaper method of K-wire fixation.
As the CIs exclude the minimum clinically important difference for the PRWE questionnaire scores, we
conclude that any difference in functional scores between treatment groups is unlikely to be important to
patients. Furthermore, secondary clinical outcomes show that there is no difference between the groups in
terms of health-related quality of life or the risk of complications. There was a borderline significant
difference in the DASH questionnaire score at one time point in favour of the locking plate, but this was
well below the minimum clinically important difference.
Kirschner-wire fixation requires significantly less surgical operating time than locking-plate fixation and a
reduced use of peri-operative antibiotics. The health economic evaluation suggests that locking-plate
fixation is unlikely to be cost-effective overall and that K-wire fixation is preferred.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
This large multicentre trial contradicts both the increasing trend towards the use of locking plates in the
treatment of distal radius fractures and the findings of previous trials, which indicated that locking plates
provide improved functional outcomes compared with K-wire fixation. The previous trials were smaller
single-centre studies.
The main limitation of the trial is that it was not possible to blind either the surgeons or the patients to
the study treatments. However, it could be argued that this is a positive feature in a pragmatic trial, as
patients would know about their proposed treatment before surgery during routine care. It should be
noted that this study excluded patients whose fracture could not be reduced by indirect means, i.e. the
results should not be generalised to the minority of patients whose fracture requires that the surgeon
expose the surface of the radiocarpal joint in order to restore the congruity of the wrist joint.
Compliance with the trial was good, with over 90% of patients receiving their allocated treatment. Some
patients did cross over to have a different form of fixation, but an analysis by treatment given did not alter
the result. The long-term outcome of patients with a fracture of the distal radius is not known. Our data
suggest that patients’ wrist function and quality of life improve over the 12 months following their surgery
but do not return to pre-injury levels. The patients in this trial will be followed up annually to determine
the prevalence of late complications such as arthritis.
In conclusion, and in contrast to both the trend in surgical practice and the previous literature, this trial
found no difference in PRWE questionnaire scores in the 12 months following K-wire fixation versus
volar locking-plate fixation. The health economic evaluation showed that the volar locking plate is not
cost-effective.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN31379280.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Fractures of the distal radius are extremely common injuries. In the Western world, 6% of women will
have sustained such a fracture by the age of 80 years and 9% by the age of 90 years.1 As the population
continues to age, these figures are likely to increase further. The optimal management of fractures of the
distal radius in adults remains controversial. There is a bimodal distribution in terms of age. Younger
patients frequently sustain complicated high-energy injuries involving the wrist joint. However, fractures of
the distal radius are also common in older patients, who are more likely to sustain low-energy fractures,
often related to osteoporosis.2 This study is designed to address both groups of patients, as the key
management issues pertain to all patients with a fracture of the distal radius.
In general, fractures of the distal radius are treated non-operatively if the bone fragments are not displaced
or the fragments can be held in a good anatomical alignment (reduction) by a plaster cast or orthotic.
However, if this is not possible then operative fixation is required. This carries inherent risks for the patient
and considerable cost implications for the NHS; much of this cost is related to the choice of fixation.3
There are several operative options but the two most common in the UK are percutaneous Kirschner-wire
(K-wire) fixation and volar locking-plate fixation using fixed-angle screws (locking plates). Each surgical
method has its own advantages and disadvantages.
Kirschner-wire fixation is a long-standing and widely practised technique. During this procedure, smooth
metal wires with a sharp point are passed across the fracture site through the skin. This is a relatively
simple, quick and minimally invasive technique, which is cheap and requires limited operative hardware.
However, as the fixation is not ‘rigid’ (the wires are inherently flexible) the wrist has to be immobilised in
plaster cast; normally for 6 weeks or until the wires are removed. There is a risk of infection where the
wires enter the skin. There is also a risk that the fracture will ‘collapse’ when the wires are removed,
leading to deformity and loss of function.4
Locking-plate fixation, in the distal radius and for other fractures, has been facilitated by recent advances in
implant technology, which allow the screws to be ‘locked’ into the plate. This produces a ‘fixed-angle’
bone–plate construct, (previously, plate-and-screw constructs relied on friction alone to maintain their
position on the bone). Although originally designed for use in osteoporotic bone specifically, the theoretical
advantages of the locking plates may equally be applied to high-energy (often multifragmentary) fractures
in younger patients. The technique has become increasingly popular in the UK and across the developed
world over the last 5 years. The procedure requires an incision over the volar (palm) side of the wrist.
The plate and screws are then applied to the bone fragments under direct vision. This produces a rigid
construct,5 and, therefore, the patients can be permitted to mobilise their wrist more quickly, potentially
reducing future stiffness. As the plate and screws can remain inside the patient permanently, the risk of
later collapse of the fracture is also smaller. However, this technique takes longer than a K-wire fixation
and there is a greater risk of serious intraoperative complications such as injury to a nerve or blood vessel.5
There is also a risk of flexor and/or extensor tendon irritation and rupture.6 The locking-plate hardware
itself is specialised and considerably more expensive; a cost-analysis of the total cost of each intervention
(Plant et al., University Hospital Coventry and Warwickshire NHS Trust, 2009, unpublished data) suggested
that the use of a locking plate increased the cost of the operation itself (total operating department
cost) threefold.
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In 2003, Handoll and Madhok7 summarised the results of a series of Cochrane reviews of randomised
controlled trials of the treatment of fractures of the distal radius and ‘exposed the serious deficiency in the
available evidence’. However, they were able to identify key areas for future research, including the area of
‘when and what type of surgery is indicated’. An influential group of academic trauma surgeons (AO UK
Research Committee chaired by Professor Keith Willett) recently identified our specific research question as
a ‘top priority’ for urgent investigation.8
Relevance of project
The clinical management of any fracture depends on several factors including the severity of the fracture
and the personal circumstances and comorbidity of the patient. These variables are generally out of the
control of the treating surgeon. However, the type of operative intervention can be determined after
the event. Although there will always be some variability in clinical practice, patients with a fracture of the
distal radius may expect a reasonably consistent approach to the operative treatment of such a common
fracture. However, for this particular injury there seems to be no consensus.2 For fractures of the distal
radius, perhaps more than any other fracture, the operative intervention varies enormously depending on
the preference, training and experience of the treating surgeon and the policy, inventory and budget of
the treating institution.
We recently performed a pilot study where the clinical details and radiological images of five patients with
a displaced fracture of the distal radius were presented independently to 33 experienced trauma surgeons
in the UK. The cases included younger patients with high-energy injuries and fragility fractures in older
patients. The surgeons were asked to provide a treatment plan for each patient. There was < 50%
agreement in the treatment regime for any individual patient. Across all of the cases, 44% of surgeons
would use volar locking plates, 28% would use K-wire fixation, 7% would use volar non-locking plates,
5% would use external fixators and 15% would treat the patient with manipulation and a plaster
cast alone.9
We intend to provide high-level evidence to inform the future management of adult patients with a
displaced fracture of the distal radius by directly comparing the results of K-wire fixation and locking-plate
fixation in a multicentre randomised controlled clinical trial.
Null hypothesis
There is no difference in the Patient-Rated Wrist Evaluation© (PRWE) questionnaire score 12 months
post injury between adult patients with a dorsally displaced fracture of the distal radius treated with
locking-plate fixation versus K-wire fixation.
Objectives
The primary objective is to quantify and draw inferences on observed differences in the PRWE
questionnaire score (a validated assessment of wrist function) between the trial treatment groups at
12 months post injury.
The secondary objectives are to quantify and draw inferences on observed differences in the Disabilities
of Arm, Shoulder and Hand (DASH) questionnaire score (a validated assessment of general upper-limb
function) between the trial treatment groups at 12 months post injury; to determine the complication
rate of K-wire fixation versus locking-plate fixation at 12 months post injury; and to investigate,
using appropriate statistical and economic analysis methods, the resource use, and comparative
cost-effectiveness, of K-wire fixation versus locking-plate fixation.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Chapter 2 Methods
Trial design
This was a multicentre, stratified (by centre, intra-articular extension of the fracture and age of the patient,
with balanced randomisation 1 : 1) double-blind, controlled trial.
Participants
Inclusion criteria
Patients were eligible for this study if:
l They sustained a dorsally displaced fracture of the distal radius, which was defined as a fracture within
3 cm of the radiocarpal joint.
l The treating consultant surgeon believed that they would benefit from operative fixation of
the fracture.
l They were over the age of 18 years and able to give informed consent.
l The injury was < 2 weeks old.
Exclusion criteria
Patients were excluded from participation in this study if:
l The fracture extended > 3 cm from radiocarpal joint.
l The fracture was open with a Gustilo grading greater than 1.10
l The articular surface of the fracture could not be reduced by indirect techniques. (In a small number of
fractures, the joint surface is so badly disrupted that the surgeon will have to open up the fracture in
order to restore the anatomy under ‘direct’ vision.)
l There were contraindications to anaesthetic.
l There was evidence that the patient would be unable to adhere to trial procedures or complete
questionnaires, such as cognitive impairment or intravenous drug abuse.
Patients who sustained other injuries, which could potentially affect the primary outcome measure at 1 year
post injury, for example disruption of the carpal ligaments, were documented but included in the analysis.
Screening and recruitment
Patients were recruited from the emergency departments and fracture clinics at the trial centres.
Any patient with a fracture of the distal radius who, in the opinion of the treating surgeon, required an
operative intervention was referred to the local research associate for screening. The research associate
then presented the eligible patient with the participant information sheet. Patients were given the
opportunity to discuss any issues related to the trial with the research associate, as well as with members
of their family and friends.
Consent
Informed consent was obtained by the local research associate. In general, patients who were admitted
with a fracture of the distal radius had their surgery on the following day, so there was sufficient time
for the patients to consider taking part in the trial. Any new information that arose during the trial that
affected participants’ willingness to take part was reviewed by the Trial Steering Committee (TSC);
if necessary this was communicated to all participants by the trial co-ordinator. A revised consent form
was completed if necessary.
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Settings and locations
The trial was run in 18 trauma centres across the UK (Box 1).
Sample size
We performed an audit of the patients who had an operative fixation of their distal radius fracture at
the University Hospital Coventry and Warwickshire (UHCW) over a 4-month period in 2007.11 This
revealed that 32 patients had either a K-wire fixation or a locking-plate fixation at our hospital during this
period. Therefore, we anticipated that there would be 90–100 eligible patients per year. As each of the
recruiting centres served a similar catchment area (c. 500,000 patients) we expected that there would be
approximately 900–1000 eligible patients within the trial centres each year. All of the centres chosen to
take part in this study regularly performed both locking-plate fixation and K-wire fixation for patients with
a fracture of the distal radius.
In previous trials performed at the lead centre, recruitment rates of between 70% and 90% were achieved
for trials comparing different surgical treatments (both elective and trauma procedures). At a conservative
estimate of 35–40% recruitment for a multicentre study, we were, therefore, confident of achieving the
recruitment target of 390 patients in 12–18 months.
BOX 1 Participating centres
Centre
1. Addenbrooke’s Hospital.
2. Frenchay Hospital.
3. Ipswich Hospital.
4. James Cook University Hospital.
5. John Radcliffe Hospital.
6. Leicester General Hospital.
7. North Tyneside General Hospital.
8. Northampton General Hospital.
9. Peterborough City Hospital.
10. Poole Hospital.
11. Royal Blackburn Hospital.
12. Royal Victoria Infirmary.
13. St Thomas’ Hospital.
14. University Hospital Coventry & Warwickshire.
15. University Hospital North Staffordshire.
16. University Hospital of North Tees.
17. Wansbeck General Hospital.
18. Wexham Park Hospital.
METHODS
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Randomisation
Those patients who consented to take part in the trial had their method of fixation allocated using a
secure, centralised telephone randomisation service. The allocated treatment was then reported back to
the research associate, who informed the patient and the treating surgeon. The surgeon then arranged the
allocated surgery on the next available trauma operating list, as per standard practice at that institution.
This ensured the integrity of the randomisation process.
Sequence generation
Randomisation was on a 1 : 1 basis, stratified by centre, intra-articular extension of the fracture and age of
the patient (above or below 50 years).
Stratification by centre helped to ensure that any clustering effect related to the centre itself was equally
distributed in the trial arms. The catchment area (the local population served by the hospital) was similar
for all of the hospitals (c. 500,000), each hospital being a major orthopaedic unit dealing with these
fractures on a daily basis. While it is possible that the surgeons at one centre may be more expert in one or
other treatment than those at another centre, all of the recruiting hospitals were chosen on the basis that
both techniques are currently routinely available at the centre, that is theatre staff and surgeons were
already equally familiar with both forms of fixation. This could not eliminate the surgeon-specific effect of
an individual at any one centre.12 However, as the fixation of a fracture of the distal radius is a common
procedure performed on routine trauma operating lists, many surgeons would be involved in the
management of this group of patients: between 10 and 30 surgeons at each centre, including both
consultants and trainees. Therefore, we expected that each individual surgeon would operate on only
two or three patients enrolled in the trial, greatly reducing the risk of a surgeon-specific effect on the
outcome in any one centre.
Stratification on the basis of intra-articular extension of the fracture (specifically involvement of the articular
surface of the radiocarpal joint) eliminated a major potential confounder, since disruption of this
articular surface may predispose to secondary osteoarthritis of the wrist.13 Recent evidence14 suggests that
other associated features of fractures of the distal radius which commonly appear in the classification
systems, such as involvement of the ulna styloid process and distal radio-ulnar joint involvement, do not
actually affect the functional outcome of the injury. Therefore, we did not include any other variables in
the stratification of the randomisation sequence.
Stratification on the basis of age was used to discriminate between younger patients with normal bone
quality sustaining high-energy fractures and older patients with low-energy (fragility) fractures related to
osteoporosis. Empirically, both of these groups of patients could benefit from the fixed-angle stability
provided by locking-plate fixation. However, the stratification would help to identify any effect related to
the quality of the patient’s bone. The use of dual-energy X-ray absorptiometry (DEXA) is widely regarded
as the gold standard for the assessment of bone density. However, such an investigation may be expensive
and not routinely available at all centres. Therefore, we used age as a surrogate for bone density. In a
large study in Norway involving 7600 participants, it was demonstrated that forearm bone mineral density
remains stable up until the age of 50 years. After the age of 50 years, bone mineral density in males
decreased steadily, while in females there was an initial decline between the ages of 50 and 65, with a
further decline in the age groups thereafter.15 A recent study by Court-Brown and Caeser16 assessed over
1000 patients with a fracture of the distal radius. This study confirmed that there is a clear bimodal
distribution for this type of fracture according to the age of the patient. The crossover of the two peaks of
incidence was around 50 years of age. These studies provide strong evidence that patients over the age
of 50 years become increasingly vulnerable to fragility fractures of the distal radius. Therefore, we chose
the age of 50 years as the cut-off for this trial. Furthermore, the study by Court-Brown and Caeser16
demonstrated that in the UK approximately 60% of patients sustaining a fracture of the distal radius are
over 50 years, while 40% are younger than 50 years. The number of patients above and below this
stratification age would, therefore, be similar (see Statistical analysis).
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Blinding
In this surgical trial, the patients could not be blinded to their treatment. The treating surgeons were,
of course, not blind to the treatment, but took no part in the postoperative assessment of the patients.
The statistical analyses were not performed blind.
Postrandomisation withdrawals
Participants could withdraw from the trial at any time without prejudice. If patients decided to have the
treatment to which they were not randomised, they were followed up wherever possible and data
collected as per the protocol until the end of the trial. The primary analysis was on an intention-to-treat
basis with a secondary per-protocol analysis.
Interventions
All of the hospitals involved in this trial used both of the methods of fixation at the time of the trial and all
of the surgeons involved were familiar with both techniques. Operative fixation of fractures of the distal
radius usually took place under a general anaesthetic, but this decision was made by the attending
anaesthetist. Patients undergoing surgical fixation for a fracture of the distal radius are placed in a supine
(lying on their back) position with the affected arm on an ‘arm-board’ extension to the operating table,
but the exact details of the positioning of the patient were left to the discretion of the treating surgeon.
A copy of the ‘operating record’ formed part of the trial data set.
Each patient underwent the allocated surgery according to the preferred technique of the operating
surgeon. Although the basic principles of percutaneous K-wire fixation and locking-plate fixation are
inherent in the technique (see Kirschner-wire fixation and Volar locking plate), there are several different
implant systems and several different options for the positioning of wires and screws. Similarly, each
surgeon made minor modifications to their surgical technique according to preference and the specific
pattern of each fracture. In this trial, the details of the surgery were left entirely to the discretion of the
surgeon to ensure that the results of the trial could be generalised to as wide a group of patients
as possible.
Although all of the surgeons in the trial were familiar with both techniques, it is possible that an
individual surgeon may have had more experience with one technique than the other. We expect that
the proficiency of an individual surgeon to perform the procedure may change over time, as the surgeon
gains experience and expertise. The term ‘learning curve’ is often used to describe this process. It was
important to monitor the learning curve for all surgeons throughout the trial. The operating time recorded
on the operative record for each surgery was used as a proxy to measure the task efficiency of the
surgeons (quality assurance of the clinical process), and the number of complications (e.g. infections) at
6 weeks after surgery was also recorded as a patient-based outcome. Given the number of centres
and surgeons taking part in this trial, no individual surgeon was likely to perform more than a small
number of the procedures. However, where data were available for individual surgeons, temporal
variations in operation times and complications at 1 week were modelled for each surgeon using a
power curve,12 for the trend with appropriate adjustment for confounding factors such as the age of
the patients. In addition, as this study involved multiple surgeons, we expected that a more complex
hierarchical model12 that fully accounted for the structure of the data might prove to be useful; therefore,
we expected fitting models of this class in addition to the simpler models. Results from the learning curve
analysis for each surgeon would inform inferences regarding overall treatment differences and if necessary
guide recommendations for implementation and training.
Kirschner-wire fixation
The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in
order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion
technique and the configuration of wires were left entirely to the discretion of the surgeon. A plaster cast
METHODS
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was applied at the end of the procedure to supplement the wire fixation as per standard surgical
practice. This cast holds the wrist still and is left on until the wires are removed at the 6-week
follow-up appointment.
Volar locking plate
The locking plate is applied through an incision over the volar (palm) aspect of the wrist. Again, the details
of the surgical approach, the type of plate, and the number and configuration of screws were left to the
discretion of the surgeon. The screws in the distal portion of the bone were ‘fixed-angle’, that is screwed
into the plate, but this is standard technique for the use of these plates. The type of proximal screw was
left to the discretion of the surgeon; these may be locking or non-locking screws, as the bone in this area
provides a much better purchase for the screws. Some surgeons used a temporary plaster cast to hold the
patients’ wrist still but the fixed-angle stability provided by the locking plate was generally sufficient to
allow early controlled range-of-movement exercises. The use of a cast or otherwise was again left to the
discretion of the surgeon as per usual practice.
Radiographic evaluation
Patients were evaluated radiographically at presentation, and then at 6 weeks and 12 months post injury.
The degree of palmar tilt, the ulnar variance and the presence of metaphyseal comminution were
determined from the calibrated digital images of the posteroanterior and lateral radiographs using the
OsiriX DICOM (Digital Imaging and Communications in Medicine) viewer (www.osirix-viewer.com).
The palmar tilt was measured as the angle between lines drawn perpendicular to the long axis and along
the distal joint surface of the radius as described by Goldfarb et al.17 and Mann et al.18 (Figure 1). Dorsal
angulation was denoted by a positive value and volar angulation by a negative value.19
FIGURE 1 Ulnar variance (the distance between the radial and ulnar articular surfaces).
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The ulnar variance was determined using the method of perpendiculars described by Steyers and Blair20
Lines were drawn along the distal ulnar aspect of the radius and the distal cortical rim of the ulnar parallel
to the perpendicular of the long axis of the radius20–22 (Figure 2). The distance between these lines
measures the ulnar variance.20
Rehabilitation
We ensured that all patients randomised into the two groups received standardised written physiotherapy
advice detailing the exercises they needed to perform for rehabilitation following their injury. All of the
patients in both groups were advised to move their shoulder, elbow and finger joints fully within the limits
of their comfort. Those patients in the K-wire group were encouraged to perform range-of-movement
exercises at the wrist as soon as their plaster cast was removed at the 6-week follow-up appointment.
Those patients in the locking-plate group could begin the exercises immediately if they did not have a
plaster cast or as soon as the cast was removed. In this pragmatic trial, any other rehabilitation input
beyond the written information sheet (including a formal referral to physiotherapy) was left to the
discretion of the treating surgeon. However, a record of any additional rehabilitation input (type of input
and number of additional appointments) together with a record of any other investigations/interventions
was requested as part of the 3-month, 6-month and 12-month postal follow-ups and this formed part
of the trial data set.
FIGURE 2 Palmar tilt (the angle between the articular surface of the radius and the perpendicular of the long axis
of the radius).
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Outcomes
The primary outcome measure for this study was the PRWE questionnaire score.23 The PRWE is a validated
questionnaire which is self-reported (filled out by the patient). It consists of 15 items specifically related
to the function of the wrist. These data were collected at baseline and 3, 6 and 12 months
postoperatively. The PRWE questionnaire score is the most sensitive outcome measure for patients
sustaining this specific injury.24
The secondary outcome measures in this trial were:
l DASH questionnaire score: the DASH outcome measure is a 30-item self-report questionnaire designed
to provide a more general measure of physical function and symptoms in people with musculoskeletal
disorders of the upper limb.25
l EuroQol – Five Dimensions (EQ-5D): the EQ-5D is a validated, generic, quality of life questionnaire
consisting of five domains related to daily activities with a three-level answer possibility. The
combination of answers leads to a health profile of five digits that can then be converted into a
utility that represents the overall quality of life of the patient.26
Complications: all complications were recorded.
Resource use was monitored for the economic analysis. Patients retrospectively reported use of primary,
secondary and community health-care use, medications and aids/instruments as well as social care,
informal care, out-of-pocket expenses and lost productivity via a short questionnaire which was
administered at 3, 6 and 12 months post surgery. Patient self-reported information on service use has
been shown to be accurate in terms of the intensity of use of different services.27,28
Follow-up measures
We used techniques common in long-term cohort studies to ensure minimum loss to follow-up, such as
collection of multiple contact addresses and telephone numbers, mobile telephone numbers and e-mail
addresses. Considerable efforts were made by the trial team to keep in touch with patients throughout the
trial by means of newsletters, etc. Data were collected at baseline and at 6 weeks, 3 months, 6 months
and 12 months post surgery (Table 1).
The PRWE23 is a 15-item questionnaire, designed specifically for assessment of distal radial fractures
and wrist injuries, that rates wrist function using a range of questions in two (equally weighted)
sections concerning the patient’s experience of pain and disability. Scoring for all the questions is via
a 10-point ordered categorical scale ranging from ‘no pain’ or ‘no difficulty’ (0) to ‘worst possible pain’ or
TABLE 1 Data collection
Time point Data collection
Baseline PRWE and DASH pre injury, EQ-5D pre injury and contemporary, radiographs
6 weeks Complication records, radiographs and operative record
3 months PRWE, DASH, EQ-5D, record of complications/rehabilitation or other interventions and
economics questionnaire
6 months PRWE, DASH, EQ-5D, record of complications/rehabilitation or other interventions and
economics questionnaire
12 months PRWE, DASH, EQ-5D, radiographs, record of complications/rehabilitation or other interventions and
economics questionnaire
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‘unable to do’ (10). Five questions relate to a patient’s experience of pain and 10 relate to function and
disability; the scores for the 10 function items are summed and divided by 2 and added to the scores
of the five pain items to give a total score out of 100 (best score= 0 and worst score= 100).
We performed a retrospective pilot study29 that obtained PRWE questionnaire scores for 84 patients
(42 each receiving either a volar locking-plate fixation or a manipulation under anaesthetic and K-wire
fixation) at 12 months after surgery. The mean PRWE questionnaire scores for the K-wire and locking-plate
groups at 12 months were 33.2 and 27.5, respectively, with a pooled standard deviation (SD) of 19. The
SD for the PRWE questionnaire score is similar to that reported for other studies of pain and disability after
fracture of the distal radius,30 which was in the range of 17–23 points.
We assumed a normal distribution for the PRWE questionnaire scores, which seemed appropriate given
that our pilot study indicated that the 12-month group mean PRWE questionnaire score would be
expected to be approximately 30 with a SD of 20. An appropriate sample size for detecting a six-point
difference between groups at the 5% level with 80% power was, therefore, 175 patients in each group
(power and sample size software, available at http://medipe.psu.ac.th/episoft/pssamplesize/). A six-point
difference between groups equates to a standardised effect size of 0.3, for an assumed SD of 20 points.
MacDermid et al.24 found that the PRWE questionnaire is sensitive enough to detect subtle but clinically
relevant changes in wrist function of this order of magnitude in patients sustaining a fracture of the
distal radius, for example changes between 3 and 6 months (effect size 0.5). At the individual level, a
change in the PRWE questionnaire score of 6 points reflects the difference between turning a doorknob or
cutting a loaf of bread with mild pain versus no pain. We believed that such an improvement would be
important to patients on an individual level and at population level and could lead to a change in clinical
practice in the UK.
However, it is also helpful to consider the effect of choosing two alternative minimal clinically important
difference (MCID) values of 5 and 7 points on the PRWE questionnaire score scale on the required sample
size for 80% power at the 5% level (Table 2).
In summary, this study used the PRWE questionnaire score at 12 months after surgery as the primary
outcome measure. The total number of patients required to obtain a power of 80% to detect a six-point
difference between groups for the primary outcome measure was 350, that is 175 patients were required
in each treatment group. In trials run previously at our institution comparing two different surgical
techniques, we experienced a ≈5% loss to follow-up. With an allowance for a conservative 10% loss to
follow-up, we planned to recruit a minimum of 390 patients.
If recruitment proceeded at a faster rate than expected, for example if there were particularly adverse
winter weather, which is known to be a primary causative factor for distal radius fractures, then there
was the possibility of increasing the overall trial sample size within the defined recruitment period.
Increasing the sample size would provide an increase in the power to detect a six-point difference between
groups for the primary outcome measure above the set level of 80%. Recruitment was monitored and
discussed at monthly Trial Management Group (TMG) meetings and, where appropriate, recruitment
projections were undertaken to assess this possibility. See Appendix 1 for details of recruitment projections
and new sample sizes for increasing power.
TABLE 2 Effect of choosing alternative MCID values
MCID Standardised effect size Sample size per group
5 0.25 252
6 0.30 175
7 0.35 129
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Adverse event management
Adverse events are defined as any untoward medical occurrence in a clinical trial subject and which do not
necessarily have a causal relationship with the treatment. All adverse events were listed on the appropriate case
report form for routine return to the Distal Radius Acute Fracture Fixation Trial (DRAFFT) central office.
Serious adverse events (SAEs) were defined as any untoward and unexpected medical occurrence that:
l results in death
l is life-threatening
l requires hospitalisation or prolongation of existing inpatients’ hospitalisation
l results in persistent or significant disability or incapacity
l is a congenital anomaly or birth defect
or any other important medical condition which, although not included in the above, may require medical
or surgical intervention to prevent one of the outcomes listed.
All SAEs were entered onto the serious adverse event reporting form and given to the DRAFFT central
office within 24 hours of the investigator becoming aware of them. Once this was received, causality and
expectedness were determined by the chief investigator. SAEs that were deemed to be unexpected
and related to the trial were notified to the Research Ethics Committee (REC) within 15 days for a
non-life-threatening event and within 7 days for a life-threatening event. All such events were reported to
the TSC and Data Monitoring Committee (DMC) at their next meetings. SAEs that were expected as part
of the surgical interventions, and that did not need to be reported to the main REC, were complications
of anaesthesia or surgery (e.g. wound infection, delayed wound healing and thromboembolic events).
All participants experiencing SAEs were followed up as per protocol until the end of the trial.
Risks and benefits
The risks associated with this study were predominantly the risks associated with the surgery: infection,
bleeding and damage to the adjacent structures such as nerves, blood vessels and tendons. Participants in
both groups underwent surgery and were potentially at risk from any/all of these complications. The
application of the locking plates requires a surgical incision over the volar aspect of the wrist, which,
empirically, may lead to a higher risk of injury to the adjacent structures. However, the evidence available
to quantify this risk was limited.13 Late attrition and rupture of the extensor tendons have been associated
with volar locking plates,31 but, equally, late collapse and secondary deformity have been associated with
K-wire fixation.19 The risk of secondary (as a result of the injury) osteoarthritis of the wrist joint, particularly
in those patients with intra-articular extensions of the fracture, is well recognised,13 but there were no
data to suggest what that risk is or that the risk is greater in one group or another. We believed that the
overall risk profile was similar for the two interventions but an assessment of the number of complications
in each group was a secondary objective of this trial.
Statistical analysis
Analysis plan
The statistical analysis plan was agreed with the DMC at the start of the study. Any subsequent
amendments to this initial plan are clearly stated and justified. Interim analyses were performed only where
directed by the DMC. The trial registration details were updated soon after the start of the trial; this was
not a change to the statistical analysis plan, but merely the inclusion of extra detail in the registration
document, which was added at the suggestion of the DMC.
DOI: 10.3310/hta19170 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 17
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
Software
The routine statistical analysis was carried out using R version 3.0.1 (The R Foundation for Statistical
Computing, Vienna, Austria, www.r-project.org/). When any analyses were required, data were retrieved
from the trial database by the trial statistician. The statistician imported data directly into the statistical
package R for analysis and reporting. The version numbers of all software used, data files and all R scripts
were made available to the DMC on request at any stage of the trial. Statistical results were reported in
accordance with Consolidated Standards of Reporting Trials (CONSORT) guidelines (www.consort-
statement.org/).
Data validation
Prior to formal analysis, data were checked for outliers and missing values and validated using the defined
score ranges for all outcome measures. Queries were reported to the trial co-ordinator and investigated.
Standard statistical summaries (e.g. medians and ranges or means and variances, dependent on the
distribution of the outcome) and graphical plots showing correlations were presented for the primary
outcome measure and all secondary outcome measures. Baseline data were summarised to check
comparability between treatment arms, and to highlight any characteristic differences between those
individuals in the study, those ineligible for the study, and those eligible but withholding consent.
Missing data
As seemed likely at the outset, some data were not available because of the voluntary withdrawal
of patients, lack of completion of individual data items or general loss to follow-up. Where possible,
the reasons for data ‘missingness’ were ascertained and reported. Although missing data were
not expected to be a problem for this study, the nature and pattern of the missingness were carefully
considered – including, in particular, if data could be treated as missing completely at random (MCAR).
If judged appropriate, we planned to impute missing data using the multiple imputation facilities
(mice package) available in R. Any imputation methods used for scores and other derived variables were
carefully considered and justified. We planned that if the degree of missingness was relatively low, as
expected, the primary analysis would be based on complete cases only (complete case analysis), with
analysis of imputed data sets used to assess the sensitivity of the analysis to the missing data. Reasons for
ineligibility, non-compliance, withdrawal or other protocol violations would be stated and any patterns
summarised. More formal analysis, for example using logistic regression with ‘protocol violation’ as a
response, was also considered if appropriate and if it aided interpretation.
Interim analyses
Interim analyses were performed only where directed by the DMC. Any interim analyses would follow the
same procedure as the final analyses.
Final statistical analyses
Null hypothesis
We considered that, while it may be of interest to the patient to know the time from surgery to returning
to ‘normal’ function, our previous experience of collecting data related to this outcome has been very
difficult. In addition, there is no clear formal definition of when a fracture can be considered to have fully
healed and the patient is able to return to normal activity. This would be necessary if the time to this event
were potentially to be used as the primary outcome measure in this trial. Therefore, for these reasons
and as the practical difficulties and cost implications for a time-to-event analysis would be considerable,
the main analysis investigated differences in the primary outcome measure, the PRWE questionnaire score
at 12 months after surgery, between the two treatment groups (K-wire fixation and locking-plate fixation)
on an intention-to-treat basis.
Null hypothesis: there is no difference in the PRWE questionnaire score 12 months post injury between
adult patients with a dorsally displaced fracture of the distal radius treated with locking-plate fixation and
those treated with K-wire fixation.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
In addition to the analysis at 12 months post injury, early functional status was also assessed and reported
at 3 months and 6 months.
Multilevel model
Differences between treatment groups were assessed, based on a normal approximation for the PRWE
questionnaire score, at 12 months postoperatively, and at interim occasions. Tests were two-sided
and considered to provide evidence for a significant difference if p-values are < 0.05 (5% significance level).
Estimates of treatment effects were presented with 95% confidence intervals (CIs).
The stratified randomisation procedure should have ensured a balance in age, intra-articular extension and
the recruiting centre between test treatments. Although generally we had no reason to expect that the
clustering effects would be important for this study, in reality the data were likely to be hierarchical in
nature, with patients naturally clustered into groups by recruiting centre and surgeon. Therefore, we
proposed to account for this by generalising the conventional linear (fixed-effects) regression approach to a
more general multilevel modelling approach; where patients are naturally grouped by surgeons and,
likewise, surgeons are grouped by recruiting centres. This model would formally incorporate terms that
allowed for possible heterogeneity in responses for patients owing to the recruiting centre and the
surgeon, in addition to the fixed effects of the treatment groups, patient age and intra-articular extension.
As discussed earlier, we expected that each individual surgeon would operate on only a small number
(two or three) of the patients enrolled in the trial, which would greatly reduce the likelihood of a
surgeon-specific effect on the outcome. Therefore, although we considered formally constructing a model
with two levels of clustering (recruiting centre and surgeon), we expected that, if there were sparse data
on individual surgeon effects, the final model would be simplified and consist of single random effect
accounting for the recruiting centre only.
The main analyses were conducted using specialist multilevel modelling functions available in the software
package R. PRWE questionnaire data were assumed to be normally distributed, although we considered
the possibility of appropriate variance-stabilising transformation. The primary focus was the comparison
of the two treatment groups of patients, and this was reflected in the analysis, which was reported
together with appropriate diagnostic plots that check the underlying model assumptions. Although
baseline PRWE questionnaire scores were recorded using a retrospective assessment by each patient
post injury, these were not considered to be sufficiently reliable for formal baseline adjustment in the
multilevel model. Mean baseline PRWE questionnaire scores together with other patient demographic
data (e.g. age and gender) were reported for each treatment group to assess population comparability
post randomisation.
The interactions between the stratifying variables (age and intra-articular extension) and the main
treatment effect were not expected to be large; therefore, for practical reasons, the study was not
powered with subgroup analysis in mind, as this would require a substantial and unrealistic increase in
overall sample size. However, analyses were planned for each of the stratifying variables, particularly
for participants aged over 50 years, who constitute a sizeable and important subgroup within the full study
population. Formal tests of interaction between each stratifying variable and the treatment factor were
reported together with appropriate 95% CIs and p-values. Significant results from this analysis were
interpreted with due caution and reported as such, in line with recommendations for subgroup analysis
made elsewhere.32
Complications
The temporal patterns of any complications were presented graphically and if appropriate a time-to-event
analysis (Kaplan–Meier survival analysis) was considered to assess the overall risk and risk within individual
classes of complications (e.g. infection). This was to be the primary analysis for complications. However,
if multiple complications proved to be widely reported then a Poisson regression model (or zero-inflated
Poisson regression model) was planned to assess overall differences in counts of events between groups,
adjusting for potential confounding factors such as age and gender. Multiple complications were defined
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as two or more independent events, that is, not continuations of a previous complication, in the same
patient and were identified only after discussion with the clinical team.
Reporting
Wherever possible, the results of all analyses were presented in a simple and easy-to-follow manner and
related any observed differences to their clinical importance, so that they could be clearly understood
by those with only rudimentary statistical knowledge. Open and confidential reports of the statistical
analyses were planned, as required, by the trial statistician and, where appropriate, results were to be
disseminated through peer-reviewed journals, conference presentations and local mechanisms.
Health economic analysis plan
Objectives
The economic evaluation was designed to estimate costs of distal radial fractures treated by locking-plate
fixation and by K-wire fixation. If appropriate, the primary objective was to evaluate the incremental
cost-effectiveness of distal radial fractures treated by locking-plate fixation versus K-wire fixation.
A within-trial analysis comparing the outcomes and costs up to 12 months’ follow-up using trial data was
undertaken for two age groups: (1) patients < 50 years of age and (2) patients ≥ 50 years of age.
The evaluation followed the reference case guidance for technology appraisals set out by the National
Institute for Health and Care Excellence (NICE).33
In the longer term, we will develop a cost-effectiveness analysis modelling outcomes and costs up to
10 years post surgery. The methods for this second analysis will be presented in due course. However, the
results for this analysis are not presented in the present report; this will require longer follow-up data,
which are not currently available.
Measurement of outcomes
The economic analysis used quality-adjusted life-years (QALYs) to measure health outcomes. Health-related
quality of life was estimated using responses from the EuroQol – Five Dimensions 3 Level.26 Patients
completed the EQ-5D questionnaire at baseline, 3 months, 6 months and 12 months after randomisation
as secondary outcomes of the trial. Standard UK tariff values were applied to these responses at each time
point to obtain utility. QALYs were calculated as an ‘area under the curve’ and formed the main outcome
measure of the study. In addition, patients self-completed EQ-5D assessing their pre-injury quality of
life retrospectively.
Measurement of costs
Patient-reported data on resource usage were collected within the trial at 3 months, 6 months and
12 months. For the 3-month data, the recall period was since discharge from hospital. For the other cases,
it was since the last questionnaire was due to be completed. The questionnaires included number of
further inpatient stays following the initial operation (including specialty and length of stay), number of
outpatient, primary and community care visits, use of aids and adaptations, and medication use. Patients
also reported the use of personal social services related to their treatment, as well as private costs such as
treatments within private settings and time off work. Personal social services included number of weeks of
frozen/hot meals on wheels, laundry services and number of visits of carers and social workers.
Costs were estimated combining patient-reported resource usage with unit cost data obtained from
national databases such as the British National Formulary (BNF) and Personal Social Services Research Unit
(PSSRU) Costs of Health and Social Care.34 Any unit cost that was not available was estimated in
consultation with the UHCW finance department.
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The analyses initially took the perspective of the NHS including the costs of health and social care.
Subsequent analyses adopted a societal perspective taking into account productivity costs (time away from
work) and out-of-pocket expenditures incurred by patients in relation with their treatment. The currency
used is pounds sterling (£).
Missing data
Although missing data were not expected to be a problem in this study, the economic analyses followed
the nature and pattern of the missingness reported by the statisticians. This was illustrated as MCAR,
missing at random or not missing at random.
A base-case analysis of the complete data set was conducted including only patients with complete cost
and QALY data.
We then explored the use of the last observation carried forward (LOCF) approach to deal with missing
values. Costs and EQ-5D values were carried forward for only one successive missing observation.
Finally, we imputed missing data through multiple imputations.35,36 This method, assuming that data are
missing at random, replaces the missing values with plausible substitutes based on the distribution of
observed data and, by using iterative multivariable regression techniques, includes randomness to reflect
uncertainty. All baseline variables were used to impute missing data. This approach is recommended for
economic analyses alongside clinical trials, as it reflects the uncertainty inherent in replacing missing data.12
We considered the impact on the cost-effectiveness results using both imputation methods in the
sensitivity analyses.
Within-trial analysis
Main characteristics of the analysis
The within-trial analysis aimed to determine the intervention that would maximise health outcomes
(1) within the limited NHS budget and (2) within a societal perspective over the 12-month trial follow-up.
It adopted an intention-to-treat perspective and consisted of a cost–utility analysis over 12 months
examining the cost per QALY gained for all patients. As the analysis uses a 1-year time horizon,
discounting for the future cost and health outcome is not necessary in this analysis. We calculated the
incremental cost-effectiveness ratios by dividing the average difference in cost between the two arms by
the average difference in QALYs between the two arms as follows:
ICER =
(mean costlocking-plate − mean costK-wire)
(mean QALYlocking-plate − mean QALYK-wire)
(1)
The incremental cost-effectiveness ratio (ICER) represents the additional cost per unit of outcome gained.
This indicates the trade-off between total cost and effectiveness when choosing between volar
locking-plate fixation and K-wire fixation. When compared against the marginal trade-off for the NHS as a
whole – the cost-effectiveness threshold – this gives an indication of whether or not spending additional
money on volar locking-plate fixation appears efficient. As a guideline rule, we used the NICE implicit cost per
QALY threshold of £20,000–30,000 per QALY to determine cost-effectiveness. NICE accepts an intervention
with an ICER of less than £20,000 per QALY as cost-effective and generally states that an intervention costing
more than £30,000 per QALY is not considered cost-effective. The more expensive intervention was
considered cost-effective as long as its ICER is within or below the £20,000–30,000 per QALY range.
Uncertainty
The non-parametric bootstrapping approach was used to determine the level of sampling uncertainty
around the ICER by generating 10,000 estimates of incremental costs and benefits. We planned to present
cost-effectiveness scatter plots illustrating the uncertainty surrounding the cost-effectiveness estimates.
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The cost-effectiveness acceptability curves (CEACs) were derived by plotting the bootstrapped estimates.
The bootstrap approach is a non-parametric method that considers the original sample as though it
were the population and draws multiple random samples from the original sample. The CEACs illustrated
the probability that a treatment is cost-effective in relation to a comparator, as a function of the threshold
willingness to pay (WTP).12 These were constructed using the net benefit approach. The standard
non-parametric method for constructing CEACs is to bootstrap 10,000 samples from the original data, in
order to plot the proportion of times each treatment represents the maximum average net benefit for a
range of values of WTP values. Net monetary benefit (NMB) is calculated for each bootstrap estimate for
a range of ceiling ratios as follows:
NMB = (λ QALYs) − costs, (2)
where λ is the value a decision-maker would be willing to pay.
The intervention with NMB> 0 should be adopted taking into account the NHS WTP threshold. A series
of net benefits were calculated for relevant λ values ranging from £0 to £50,000 (£5000 increments) to
incorporate the £20,000–30,000 per QALY gain threshold range currently specified for NICE
decision-making in England and Wales.32
Mean incremental net benefits between the two arms were reported, with 95% bootstrap CIs calculated
using the bias-corrected method.37
Sensitivity
We planned to undertake univariate sensitivity analyses to explore key uncertainties in the
scenarios considered.
The results for complete cost and quality of life data (i.e. those with no missing data) as well as a strict
per-protocol analysis of the data were provided to identify the impact of missing data on the analysis and
any sensitivity to protocol violations.
As patients might also recover function within the first 3 months (rather than continuously to 3 months),
a quicker initial recovery was explored in QALY calculations, where each patient’s quality of life was
assumed to reach its observed 3-month level at 6 weeks postoperatively.
The cost assumptions in the analysis were modified if relevant (e.g. least expensive implant).
Sensitivity analyses were also planned to consider stratified analyses by factors such as age, gender, trial
centre, baseline PRWE and DASH questionnaire scores, and intra-articular extension, if this was found
to affect quality of life within the trial period.
Longer-term analysis
For the longer term, we will use decision-analytic modelling to compare locking-plate fixation and K-wire
fixation for distal radial fractures over a longer time frame. We will use a 10-year Markov decision
model based upon within clinical trial results to estimate the long-term effectiveness of fixations and the
proportional hazards of complications and also revision in both people < 50 years of age and people
≥ 50 years of age.
The model will include four possible states: (1) successful fixation; (2) complications; (3) revised fixation/
surgery; and (4) death and its structure (Figure 3).
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The impact of complications and subsequent revision surgery will be assessed using information from
various sources: the extrapolation of within-trial data and the longer complication follow-up data which is
currently ongoing, the published literature and/or expert opinions to create the most accurate model to
compare locking-plate fixation and K-wire fixation for distal radial fractures. We will conduct a systematic
review of cost-effectiveness models in the treatment distal radius fracture. This will act as the main
resource of transition probabilities for the model. Where possible, transition probabilities will be based on
the latest UK studies reflecting current care pathways and associated expectations relating to long-term
patient functioning.
Two different base case scenarios will be considered, < 50 years of age cohort and ≥ 50 years of age
cohort, both followed for 10 years.
Following the NICE reference case,33 costs and benefits will be discounted at 3.5% and a NHS
perspective adopted.
Deterministic one-way sensitivity analysis will be performed to check the results over a plausible range of
prior distributions placed on the time-varying model parameters. Multiway deterministic sensitivity analyses
will be undertaken by modelling optimistic (‘best case’) and pessimistic (‘worse case’) scenarios.38
Reporting
The results of the within-trial analyses are presented such that people with basic cost-effectiveness analysis
knowledge can understand it.
It was planned that results would be disseminated through peer-reviewed journals, conference
presentations and other types of research work dissemination. We expected to provide the within-trial
analysis results for the trial main paper and we aimed at producing one extra paper focusing on the
full health economics analysis with more mature data in the longer term.
Ethical approval and monitoring
Standard NHS cover for negligent harm was in place. There was no cover for non-negligent harm.
Ethics committee approval
The DRAFFT trial was approved by the Coventry Research Ethics Committee in February 2010
(REC reference 10/H1210/10) and by the research and development department of each participating
centre. The final approved study protocol has been published.
Successful
fixation
Major
complications
Revised
fixation
Death
FIGURE 3 States and allowable state transitions corresponding to use of a distal radius acute fracture fixation.
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Trial management group
The day-to-day management of the trial was the responsibility of the trial co-ordinator, based at Warwick
Clinical Trials Unit (CTU) and supported by the CTU administrative staff. This was overseen by the TMG,
which met monthly to assess progress. It was also the responsibility of the trial co-ordinator to undertake
training of the research associates at each of the trial centres. The trial statistician and health economist
were closely involved in the setting up of data capture systems and the design of databases and
clinical reporting forms.
Trial Steering Committee
A TSC was responsible for monitoring and supervising the progress of the DRAFFT trial. The TSC consisted
of four independent experts, a lay member and leading members of the TMG. Membership of the TSC
is given in Acknowledgements.
Data Monitoring Committee
The DMC was independent of the trial and was tasked with monitoring ethical, safety and data integrity.
The trial statistician provided data and analyses requested by the DMC at each of the meetings.
Membership of the DMC is given in Acknowledgements.
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Chapter 3 Results
Screening
Overall
The overall flow of patients in the trial is shown in Figure 4. The total number of patients screened was
12,162; Table 3 shows the age and gender split.
The overall median age of screened patients, where data were available, was 53 years [interquartile range
(IQR) 18–72 years]; for females it was 63 years (IQR 39–77 years) and for males 23 years (IQR 12–48 years).
There was clear bimodality in the age distributions for each gender (Figure 5), particularly for females.
A Gamma mixture model, gammamixEM function in R package mixtools, was fitted to data from each
gender to estimate the proportionate split and median ages in each group; bootstrapping (n= 100) was
used to estimate 95% CIs for these statistics.
The modelling suggests that, for females, the ‘young’ group has a median age of 25.1 years (95% CI 24.1
to 25.8 years) and the ‘old’ group has a median age of 71.1 years (95% CI 70.6 to 71.5 years), with the
split by group (young : old) given by 32.3% : 67.7% (95% CI 30.8 to 33.5). For males, the ‘young’ group
has a median age of 19.7 years (95% CI 18.3 to 20.6 years) and the ‘old’ group has a median age of
63.7 years (95% CI 61.3 to 65.1 years), with the split by group (young : old) given by 73.5% : 26.5%
(95% CI 69.3 to 76.0).
A recent study by Court-Brown and Caeser16 assessed over 1000 patients with a fracture of the distal
radius. This study suggested that there is a clear bimodal distribution for this type of fracture according to
the age of the patient; with a crossover of the two peaks of incidence at around 50 years of age. This was
also the case for our data, for both males and females, with Figure 5 showing that the approximate
division between the two age groups was also at around 50 years. Stratification on the basis of age was
used to discriminate between younger patients with normal bone quality sustaining high-energy fractures
and older patients with low-energy (fragility) fractures related to osteoporosis.
Eligibility
Figure 4 shows that the total number eligible for the study was 639, that is the total number screened
(12,162) minus the total number ineligible (11,523). The main reasons for patient ineligibility were that the
fracture did not require fixation (32.1%), the fracture was dorsally displaced > 3 cm from the radiocarpal
joint (26.1%) and the patient was aged < 18 years (27.8%).
Willingness
Of the 639 eligible patients, 461 (72.1%) were willing and 178 were unwilling to take part in the trial. The
main reason for being unwilling to participate was a simple unwillingness to be part of a research project
(55 patients; 30.9%). Of those patients who expressed a preference, there was a balance between the
treatment groups, with 26 patients stating a preference for wires (14.6%) and 29 stating a preference for
a plate (16.3%).
In total, 461 patients were willing to participate in the DRAFFT study. The gender and age of the
individuals who were willing and unwilling to participate in the study are shown in Table 4 and the
distribution of ages by gender and group in Figure 6.
A t-test showed that ages did not differ significantly between groups (p= 0.088) and a chi-squared test
showed no difference in gender split between groups (p= 0.301).
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TABLE 4 Age and gender of participants who were willing and unwilling
Characteristic Willing (n= 461) Unwilling (n= 178)
Age in years, mean (SD) 58.8 (15.9) 56.1 (18.8)
Gender (% female) 83.0 79.1
TABLE 3 Numbers and percentages of screened patients by gender and age group
Gender
Age group (years)
Total, n (%)a< 50, n (%) ≥ 50, n (%)
Female 2317 (21.6) 4806 (44.7) 7123 (66.3)
Male 2798 (26.0) 830 (7.7) 3628 (33.7)
Total 5115 (47.6) 5636 (52.4) 10,751 (100.0)
a Total screened n= 12,162; missing only age n= 560, missing only gender n= 81 and missing both age and
gender n= 770.
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FIGURE 5 Age distribution of screened patient bars and fitted distributions for (a) females (n= 7123) and
(b) males (n= 3628).
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Recruitment
The trial planned to recruit as a minimum 390 patients in total. Formal recruitment started on 1 January 2011
and finished on 30 June 2012. Recruitment took place at 18 centres (Table 5).
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80
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FIGURE 6 Box plot showing age distribution by gender and willingness to participate in trial. F, female; M, male.
TABLE 5 Participating centres and centre codes
Centre Code
1. Addenbrookes Hospital ADH
2. Frenchay Hospital FRH
3. Ipswich Hospital IPH
4. James Cook University Hospital JCH
5. John Radcliffe Hospital JRH
6. Leicester General Hospital LGH
7. North Tyneside General Hospital NTG
8. Northampton General Hospital NGH
9. Peterborough City Hospital PCH
10. Poole Hospital POH
11. Royal Blackburn Hospital BBH
12. Royal Victoria Infirmary RVI
13. St Thomas’ Hospital STH
14. University Hospital Coventry and Warwickshire UHC
15. University Hospital North Staffordshire UNS
16. University Hospital of North Tees NTH
17. Wansbeck General Hospital WGH
18. Wexham Park Hospital WPH
RESULTS
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Overall
Overall trends in recruitment are shown in Figure 7; the final number of participants recruited to the study
was 461 (Table 6).
The final number of recruited participants was above the initial target of 390.
Recruitment proceeded at a faster rate than expected; therefore, the decision was taken to allow the
sample size to increase above the target of 390 patients.
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3. WGH 31
4. FRH 29
5. BBH 26
6. ADH 24
7. JCH 24
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9. JRH 23
10. UNS 21
11. NGH 20
12. POH 20
13. STH 18
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16. WPH 10
17. NTH 8
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FIGURE 7 Overall DRAFFT recruitment (thick black line) and recruitment by centre (January 2011 to June 2012);
logarithmic scale used to enhance detail for individual centres. Original target= 390 patients.
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Population characteristics
The randomisation was stratified by hospital, age group and intra-articular extension. Table 7 shows
recruitment numbers by treatment group, age group and intra-articular extension.
The breakdown by age, gender and treatment group is shown in Table 8.
The majority (304 out of 461) of patients recruited to the trial were female and ≥ 50 years of age,
as expected.
TABLE 6 Recruitment by hospital and treatment group
Hospital
Treatment group
Total Months open Rate (per month)K-wire Locking plate
UHC 50 50 100 23 4.51
RVI 30 30 60 19 3.21
WGH 15 16 31 12 2.58
FRH 15 14 29 18 1.62
BBH 13 13 26 11 2.53
ADH 12 12 24 17 1.50
JCH 13 11 24 17 1.47
IPH 11 12 23 18 1.32
JRH 11 12 23 13 1.78
UNS 10 11 21 15 1.48
NGH 11 9 20 11 1.86
POH 9 11 20 13 1.58
STH 8 10 18 14 1.30
LGH 6 5 11 11 1.09
PCH 6 5 11 10 1.15
WPH 5 5 10 7 1.64
NTH 4 4 8 5 1.78
NTG 1 1 2 1 4.68
Average – – – 13.05 1.96
Total 230 231 461 235 –
TABLE 7 Recruitment by treatment group, age group and intra-articular extension
Age group, years Intra-articular extension
Treatment
TotalK-wire Locking plate
< 50 No 31 33 64
Yes 29 27 56
≥ 50 No 91 89 180
Yes 79 82 161
Total 230 231 461
RESULTS
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Surgeons and operations
Before proceeding to analyse the outcomes, it is informative to look at the details of the
surgical procedures.
Surgeons
Treatments were undertaken by 244 different surgeons; the median number of operations per surgeon
was 1 (IQR 1–2). Figure 8 shows a histogram of the number of procedures undertaken by each surgeon.
As expected, any individual surgeon operated only on a small number of patients (n= 2 or 3) enrolled in
the study; 88% of surgeons (215 out of 244) treated fewer than three study participants. This greatly
reduces the likelihood of a surgeon-specific effect on the outcome at any one centre, that is one
particularly good or bad surgeon dominating the other surgeons in the study.
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FIGURE 8 Histogram of numbers of operation for each surgeon.
TABLE 8 Recruitment by treatment group, age group and gender
Age group, years Gender
Treatment
TotalK-wire Locking plate
< 50 Female 35 46 81
Male 25 14 39
≥ 50 Female 156 148 304
Male 14 23 37
Total 230 231 461
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Operations
Details of the surgeon grade and experience and methods employed for each procedure are shown in
Table 9 and operation times by surgeon grade are shown in Figure 9.
There was no evidence to suggest that operation times differed between surgeon grades.
TABLE 9 Surgeon grade, experience and methods employed for each operation
Details of surgeons and surgery K-wire (n= 230) Locking plate (n= 231)
Perioperative antibiotic (no : yes) 58 : 164 (71%) 19 : 191 (83%)
Operated wrist (right : left) 101 : 24 (54%) 102 : 124 (54%)
Intraoperative problems (no : yes) 222 : 4 (2%) 219 : 4 (2%)
Surgeon grade, n (%)a
Consultant 60 (26) 71 (31)
Specialist trainee 102 (44) 106 (46)
Staff grade/associate specialist 30 (13) 29 (13)
Other 34 (15) 20 (9)
Surgeon experience (number of prior operations), n (%)a
0 0 (0) 1 (0)
< 5 11 (5) 8 (3)
5–10 16 (7) 23 (10)
11–20 25 (11) 30 (13)
> 20 171 (74) 158 (68)
Wires, n (%)
Number of wires useda
1 1 (0) –
2 96 (42) –
3 105 (46) –
> 3 5 (2) –
Wire sizea
1.6mm 187 (81) –
1.1mm 1 (0) –
Other 12 (5) –
Techniquea
Kapandji 54 (23) –
Interfragmentary 78 (34) –
Mixed technique 71 (31) –
RESULTS
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TABLE 9 Surgeon grade, experience and methods employed for each operation (continued )
Details of surgeons and surgery K-wire (n= 230) Locking plate (n= 231)
Plates, n (%)
Number of screws useda
3 – 20 (9)
4 – 62 (27)
5 – 42 (18)
> 5 – 88 (38)
Proximal screwa
Locking – 103 (45)
Non-locking – 110 (48)
Operation time
Minutes 31 66
Median (IQR) 24 (45) 50 (85)
Mean (SD) 37.2 (19.8) 69.9 (27.7)
Length of stay
Days 1 1
Median (IQR) 0 (1) 0 (1)
a Where numbers do not add to treatment group size, this indicates that there were some missing data.
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FIGURE 9 Operation times by surgeon grade and procedure.
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Outcomes
Treatment allocation
Table 10 shows the treatment allocation and the treatments received by treatment group. In the K-wire
group 90.4% of participants received their allocated intervention and in the locking-plate group 92.2%
received their allocated intervention.
Unless stated otherwise, all analyses reported here will be on an intention-to-treat basis, that is by
allocated treatment.
Baseline characteristics
The baseline characteristics are well balanced between treatment groups (Table 11).
Imaging outcomes
Dorsal angle (°) and ulnar variance (mm) data were extracted from available images from all study
participants before their operation (pre-op), and 6 weeks and 12 months postoperatively. In addition to the
principal clinician extracting these images (assessor 1), an additional clinician (assessor 2) also assessed
and extracted data independently. Table 12 shows estimates of intraclass correlation coefficients (ICCs),
with 95% CIs based on 1000 bootstrapped samples, for dorsal angle and ulnar variance data at the
preoperative assessment, and at 6 weeks and 12 months postoperatively. The ICC provides a measure of
agreement between the two assessors and can be interpreted as follows: 0 to 0.2 poor, 0.2 to 0.4 fair,
0.4 to 0.6 moderate, 0.6 to 0.8 substantial and 0.8 to 1.0 almost perfect.
TABLE 10 Treatment allocation
Received
Allocated
K-wire, n Locking plate, n Total, n
K-wire 208 9 217
Locking plate 18 213 231
Other 4 9 13
Total 230 231 461
RESULTS
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TABLE 11 Baseline characteristics of 461 participants; data shown are mean (SD) unless indicated otherwise
Baseline characteristics K-wire (n= 230) Locking plate (n= 231)
Sex (female : male) 191 : 39 (17%) 194 : 37 (15%)
Intra-articular extension (no : yes) 122 : 108 (47%) 122 : 109 (47%)
Age (years) 59.7 (16.4) 58.3 (14.9)
Injury side (right : left) 101 : 123 (53%) 101 : 124 (54%)
Handedness (right : left) 196 : 32 (14%) 202 : 26 (11%)
Previous problem on injured side (no : yes) 197 : 33 (14%) 191 : 39 (17%)
BMI (kg/m2) 24.8 (4.0) 26.5 (5.3)
Osteoporosis (no : yes) 208 : 22 (10%) 211 : 20 (9%)
Regular analgesia (no : yes) 160 : 70 (30%) 169 : 61 (26%)
Smoker (no : yes) 180 : 50 (22%) 189 : 42 (18%)
Mechanism of injurya
Low-energy fall 190 (83%) 189 (82%)
High-energy fall 36 (16%) 36 (16%)
Road traffic collision 1 (0%) 4 (2%)
Crush 1 (0%) 0 (0%)
Other 2 (1%) 2 (1%)
Fracture classificationa,b
A1 : A2 : A3 0 (0%) : 73 (32%) : 84 (37%) 0 (0%) : 71 (31%) : 78 (34%)
B1 : B2 : B3 1 (0%) : 1 (0%) : 1 (0%) 4 (2%) : 1 (0%) : 0 (0%)
C1 : C2 : C3 33 (14%) : 26 (11%) : 7 (3%) 30 (13%) : 34 (15%) : 11 (5%)
Alcohol consumption (per week)a
0–7 units 164 (71%) 164 (71%)
8–14 units 39 (17%) 45 (19%)
15–21 units 16 (7%) 14 (6%)
> 21 units 11 (5%) 8 (3%)
Pre-injury scores (retrospectively)
PRWE 2.6 (8.4) 2.8 (8.7)
DASH 5.4 (12.7) 4.6 (10.8)
EQ-5D 0.92 (0.17) 0.94 (0.15)
Patient preference (after randomisation)
K-wire 38 (17%) 39 (17%)
Locking plate 35 (15%) 42 (18%)
No preference 156 (68%) 150 (65%)
BMI, body mass index.
a Where totals for categorical variables do not sum to treatment group totals, it indicates that some data were missing.
b A1, extra-articular ulnar fracture with intact radius; A2, extra-articular radius fracture, simple or impacted;
A3, extra-articular multiple fragmented fracture; B1, partially-articular fracture with trace at sagittal plane;
B2, partially-articular fracture with dorsal fragment; B3, partially-articular fracture with volar fragment;
C1, complete-articular simple metaphyseal trace; C2, complete-articular simple joint and multiple fragmented metaphyseal;
C3, complete-articular multiple fragmented.
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It is clear from Table 12 that for both measures there was almost perfect agreement between both
assessors. This is displayed visually by the Bland–Altman plots in Figure 10, where the difference between
data from the two assessors is plotted against the mean with 95% CIs. We conclude from the analysis
presented in Table 12 and Figure 10 that there was excellent agreement between assessors, indicating a
high level of confidence in the measurements made by the principal assessor (assessor 1). The following
comparative analysis (between intervention groups) is based purely on the data extracted from the images
by this assessor.
Image data were available from all 461 study participants before their operation (pre-op), and 6 weeks
and 12 months postoperatively. However, some data were not available for analysis because of lack of
collection, corrupted data files (which could not be opened) and poor-quality images that could not be
analysed. In summary, only six study participants (1%) had no image data available at any occasion.
Metaphyseal comminution was reported at the preoperative assessment, in addition to dorsal angle and
ulnar variance, and appeared to be well balanced across intervention groups, with 70.0% (152 out of 217)
and 70.1% (155 out of 221) of study participants being assessed affirmatively for this characteristic for the
K-wire and locking-plate groups respectively. Table 13 shows the mean and SD for imaging outcomes
at baseline, 6 weeks and 12 months postoperatively, and estimated treatment effects after adjustment at
6 weeks and 12 months. Adjusted effects were from mixed-effects regression analysis based on complete
cases with treatment group, age group, sex and intra-articular extension as covariates (fixed effects) and
recruiting centre as a random effect.
TABLE 12 Estimates of agreement (ICC) between assessors and 95% CIs (1000 bootstrap samples)
Occasion Measure n ICC 95% CI
Preoperative Dorsal angle (°) 279 0.94 0.91 to 0.96
Ulnar variance (mm) 277 0.87 0.78 to 0.94
Week 6 Dorsal angle (°) 266 0.84 0.77 to 0.90
Ulnar variance (mm) 266 0.82 0.70 to 0.92
12 months Dorsal angle (°) 208 0.87 0.81 to 0.91
Ulnar variance (mm) 209 0.89 0.82 to 0.93
ICC, intraclass correlation coefficient.
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FIGURE 10 Bland–Altman plots showing agreement between assessors 1 and 2 for dorsal angle (°) preoperatively
(a), 6 weeks (c) and 1 year (e); and for ulnar variance (mm) preoperatively (b), 6 weeks (d) and 1 year (f). Plots show
differences plotted against mean data, with 95% CIs indicated by dashed lines.
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In summary, these results indicate that there was a significantly larger (more positive) dorsal angle in the
K-wire group than the locking-plate group, at both 6 weeks and 12 months post operation. In addition,
the variability in dorsal angle was significantly less in the locking-plate group than in the K-wire group at
both 6 weeks and 12 months (F-test to compare the variances of two samples from normal populations;
p= 0.020 and p< 0.001 and ratio of variances 0.73 and 0.45, at 6 weeks and 12 months, respectively).
There was a significantly larger (more positive) ulnar variance in the K-wire group than in the locking-plate
group, at both 6 weeks and 12 months post operation. However, there was no difference in variability
between groups for ulnar variance at 6 weeks and 12 months (p= 0.615 and p= 0.081).
The image data are summarised further in the box plots of Figure 11, which clearly show the temporal
trends in data and the difference in variance between dorsal angle data between groups at 12 months
post operation.
Functional and quality of life outcomes
The primary outcome for this study is the PRWE questionnaire score23 at 12 months after surgery.
Early functional status was also assessed and reported at 3 months and 6 months. The DASH
questionnaire25 was used as a more general measure of physical function and symptoms in people
with musculoskeletal disorders of the upper limb. Quality of life was assessed using EQ-5D. Data are
summarised for each outcome measure, at each assessment occasion, in Tables 14–16. Baseline data
are retrospective measurements made by study participants to assess pre-injury function and quality
of life at recruitment. For EQ-5D, participants also made a post-injury assessment.
TABLE 13 The mean and SD of imaging outcomes at baseline, 6 weeks and 12 months postoperatively and
estimated treatment effects after adjustment at 6 weeks and 12 months
Imaging outcome
K-wire Locking plate Difference (95% CI)
p-valueMean (SD) n Mean (SD) n Raw Adjusteda
Dorsal angle (°) Baseline 23.10 (12.57) 220 22.05 (13.85) 225 –1.05 – –
6 weeks –1.16 (11.00) 215 –4.31 (9.39) 215 –3.15 –3.18 (–5.02 to –1.33) < 0.001
12 months –0.49 (12.35) 178 –5.20 (8.24) 173 –4.70 –4.64 (–6.76 to –2.53) < 0.001
Ulnar variance
(mm)
Baseline 3.26 (2.62) 219 3.55 (3.24) 222 0.29 – –
6 weeks 1.95 (2.11) 215 1.20 (2.18) 215 –0.75 –0.75 (–1.15 to –0.35) < 0.001
12 months 2.43 (2.31) 179 1.32 (2.02) 173 –1.11 –1.08 (–1.53 to –0.63) < 0.001
a Mixed-effects regression based on a complete-case analysis with treatment group, age group, sex and intra-articular
extension as covariates (fixed effects) and recruiting centre as a random effect; p-values are from analysis of variance
(ANOVA) F-test.
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FIGURE 11 Box plots of baseline and postoperative scores and trends in means (filled circles) with 95% CIs for
(a) dorsal angle and (b) ulnar variance.
DOI: 10.3310/hta19170 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 17
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
TABLE 14 Numbers of measurements, minimum, mean, median, maximum and SD of PRWE questionnaire scores at
baseline (pre injury), 3, 6 and 12 months
Treatment Measure Baseline 3 months 6 months 12 months
K-wire n 229 212 208 211
Minimum 0.0 0.0 0.0 0.0
Mean 2.6 33.9 22.3 15.3
Median 0.0 30.5 18.3 9.0
Maximum 62.5 97.0 76.0 79.0
SD 8.4 22.3 18.6 15.8
Locking plate n 229 211 206 204
Minimum 0.0 0.0 0.0 0.0
Mean 2.8 31.5 20.6 13.9
Median 0.0 27.5 16.0 7.5
Maximum 75.5 97.5 91.0 79.5
SD 8.7 22.4 17.7 17.1
TABLE 15 Number of measurements, minimum, mean, median, maximum and SD of DASH questionnaire scores at
baseline (pre injury), 3, 6 and 12 months
Treatment Measure Baseline 3 months 6 months 12 months
K-wire n 229 203 195 201
Minimum 0.0 0.0 0.0 0.0
Mean 5.4 31.1 21.1 16.2
Median 0.8 27.6 15.8 8.3
Maximum 80.0 84.2 87.5 86.1
SD 12.7 20.6 18.5 17.9
Locking plate n 227 207 199 195
Minimum 0.0 0.0 0.0 0.0
Mean 4.6 28.9 19.2 13.0
Median 0.0 22.5 14.2 6.7
Maximum 65.8 96.7 81.9 90.8
SD 10.8 21.1 17.5 15.6
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Figures 12–14 show trends in means and box plots of distribution of scores for PRWE, DASH and EQ-5D by
treatment group.
There appears to be, from a visual inspection of the plots, very little evidence for treatment group
difference for the PRWE questionnaire score but some evidence for marginally better function in the
locking-plate group than the K-wire group for the DASH questionnaire scores. Scores recover in
the postoperative period in both groups but function is still worse than before the injury (based on
retrospective assessment). Both PRWE and DASH questionnaire scores are left-skewed at the 12-month
assessment, as they approach the score minimum. There is also very little evidence for treatment group
difference for the EQ-5D score.
Table 17 shows means and SDs by treatment group. A mixed-effects linear regression model is used to
estimate treatment differences (and 95% CIs). The full (planned) model incorporated terms that allowed
for possible heterogeneity in responses for patients owing to the recruiting centre and the surgeon,
in addition to the fixed effects of the treatment groups, sex, patient age and intra-articular extension.
However, as we foresaw in the study protocol, the overwhelming majority of surgeons operated on
fewer than three patients (see Chapter 3, Surgeons and operations), so a simplified model is used that
implements a single random effect to account for the recruiting centre. Although baseline PRWE
questionnaire scores were recorded using a retrospective assessment by each patient post injury,
these were not considered sufficiently reliable for formal baseline adjustment in the multilevel model.
The interactions between the stratifying variables (age and intra-articular extension) and the main treatment
effect were not expected to be large; therefore, for practical reasons, the study was not powered with
subgroup analysis in mind. However, formal tests of interaction between each stratifying variable and the
treatment factor are reported together with appropriate 95% CIs and p-values in Table 17.
The adjusted estimate of the treatment effect for the PRWE questionnaire score for the full population is
–1.3 (95% CI –4.5 to 1.8) in favour of the locking-plate group; the p-value of 0.398 indicates that there
is no evidence for a statistically significant difference in PRWE questionnaire scores between the treatment
groups at 12 months post operation. The MCID for the PRWE questionnaire score is 6 points; therefore,
we conclude, based on our estimated CIs, that if there is a difference in functional scores between
treatment groups it is likely to be sufficiently small as to be clinically unimportant.
TABLE 16 Number of measurements, minimum, mean, median, maximum and SD of EQ-5D scores at baseline
(pre injury), post injury, 3, 6 and 12 months
Treatment Measure Baseline Post-injury 3 months 6 months 12 months
K-wire n 229 223 205 200 204
Minimum 0.1 –0.4 –0.3 –0.2 0.1
Mean 0.9 0.4 0.7 0.8 0.8
Median 1.0 0.3 0.8 0.8 0.9
Maximum 1.0 0.8 1.0 1.0 1.0
SD 0.2 0.3 0.2 0.2 0.2
Locking plate n 229 225 207 194 194
Minimum 0.0 –0.6 –0.2 0.1 –0.1
Mean 0.9 0.4 0.7 0.8 0.9
Median 1.0 0.3 0.8 0.8 0.9
Maximum 1.0 1.0 1.0 1.0 1.0
SD 0.2 0.3 0.2 0.2 0.2
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FIGURE 12 (a) Box plots of postoperative scores and (b) trends in means with 95% CIs for the PRWE
questionnaire scores.
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FIGURE 13 (a) Box plots of postoperative scores and (b) trends in means with 95% CIs for the DASH
questionnaire scores.
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The ≥ 50 years age group formed a sizeable subgroup of patients; therefore, this was identified a priori
as being of particular interest. The adjusted estimate of the treatment effect for the full population is
–2.2 (95% CI –5.8 to 1.4) in favour of the locking-plate group; the p-value of 0.338 indicates there
is no evidence for a significant interaction term between age group and treatment group.
There was some evidence for a small and marginally significant (p= 0.051) treatment effect for
the DASH score at 12 months in favour of the locking-plate group, although the effect size was small,
at –3.2 (95% CI –6.5 to 0.0). As for the PRWE questionnaire scores, an interaction test provided no
evidence that the treatment effect for DASH differed between age groups (p= 0.309) and the small
improvement in function for the plate group is evident in the over-50-years age group only. EQ-5D failed
to show any significant differences between treatment groups.
A likelihood ratio test provided no strong evidence to support the inclusion of a random-effect to model
hospital centre (p= 0.119; chi-squared test) for the primary outcome measure, PRWE questionnaire score.
In addition, the effects of age group, sex and intra-articular extension were not significant (at the 5% level)
in the fitted model for PRWE questionnaire scores [p-values 0.764, 0.090 and 0.462; F-tests from analysis
of variance (ANOVA)]. Therefore, the inferences for the PRWE questionnaire scores would be approximately
equivalent to the above if a simple t-test had been used to compare treatment groups (t-test; p= 0.396 and
95% CI for raw difference –4.5 to 1.8). The above analyses are based on assumed approximate normality
of the residuals for the PRWE questionnaire score at 12 months; the box plots in Figure 12 suggest that this
approximation is poor. The median 12-month PRWE questionnaire scores were 9.0 for the K-wire group
and 7.5 for the locking-plate group, and a Mann–Whitney test also provided no evidence to suggest that
the treatment groups differed significantly (0.127). Inferences for the DASH questionnaire score were also
equivalent between unadjusted and adjusted analysis (t-test; p= 0.055 and 95% CI for raw difference –6.6
to 0.1); median DASH questionnaire scores were 8.3 for the K-wire group and 6.7 for the locking-plate
group, and a Mann–Whitney test also provided some evidence to suggest that the treatment groups
differed significantly (0.071).
TABLE 17 Means and SDs of outcomes at 12 months postoperatively and estimated treatment effects
after adjustment
Outcome
K-wire Locking plate Difference (95% CI)
p-valueMean (SD) n Mean (SD) n Raw Adjusteda
Primary outcome PRWE questionnaire score at 12 months in all participants
All participants 15.3 (15.8) 211 13.9 (17.1) 204 –1.4 –1.3 (–4.5 to 1.8) 0.398
Primary outcome PRWE questionnaire score at 12 months in subgroups
Aged < 50 years 13.2 (13.0) 52 15.3 (16.3) 49 2.0 1.4 (–5.0 to 7.8) 0.338
Aged ≥ 50 years 16.0 (16.5) 159 13.4 (17.4) 155 –2.6 –2.2 (–5.8 to 1.4)
Intra-articular extension= no 16.7 (16.5) 110 13.2 (16.1) 105 –3.5 –3.3 (–7.6 to 1.1) 0.211
Intra-articular extension= yes 13.8 (14.9) 101 14.7(18.2) 99 0.9 0.7 (–3.8 to 5.2)
Secondary outcomes at 12 months
DASH 16.2 (17.9) 201 13.0 (15.6) 195 –3.3 –3.2 (–6.5 to 0.0) 0.051
EQ-5D 0.83 (0.19) 204 0.85 (0.19) 194 0.02 0.02 (–0.02 to 0.06) 0.353
a Mixed effects regression based on a complete case analysis with treatment group, age group, sex and intra-articular
extension as covariates (fixed effects) and recruiting centre as a random effect; p-values are from analysis of variance
(ANOVA) F-test.
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An adjusted per-protocol analysis of the PRWE questionnaire gave an adjusted treatment effect estimate of
–1.0 (95% CI –4.2 to 2.2) and p-value equal to 0.530. An adjusted per-protocol analysis of the DASH
questionnaire gave an adjusted treatment effect estimate of –3.1 (95% CI –6.3 to 0.2) and p-value equal
to 0.066.
Missing data
There are 46 study participants with missing data at the 12-month study end point; the data are 90.0%
(415 out of 461) complete. A summary of missing values, by age group and sex, for the PRWE
questionnaire at 12 months is shown in Table 18 and the full pattern of missing values is shown in
Tables 19 and 20 for K-wire and locking-plate groups, respectively. Baseline data, age group, hospital,
treatment allocation, intra-articular extension and sex were all complete.
Tables 19 and 20 show that 336 study participants (n= 168+ n= 168) had complete score data on all
occasions. There is no evidence that missingness patterns differed between treatment groups. Forty-five
study participants did not provide PRWE questionnaire score data at 12 months: 19 in the K-wire group
and 26 in the locking-plate group. The data were 90% complete for the primary outcome measure.
In total, only 19 study participants had no post-baseline data: eight in the wire group and 11 in the
plate group.
Logistic regression, with missing data coded as 1 and complete data as 0, indicated that age group and
sex were predictive of the PRWE questionnaire score missingness at 12 months; p-values from chi-squared
tests for including age and sex in the logistic regression model were 0.017 and 0.022 respectively. Males
were more likely not to complete questionnaires than females, and those < 50 years were less likely to
complete questionnaires than those ≥ 50 years of age. This is clearly apparent from an inspection of
Table 19.
Study participants aged < 50 years and males were less likely to provide complete data; experience
suggests this is not an unexpected result. Assuming that missingness is fully explained by these variables
(for which we have complete data), that is assuming that data are missing at random, our approach to
the analysis in which we adjust for the variables that are predictive of missingness is sensible and should
yield unbiased estimates of the treatment effect.
Imputing the missing data and rerunning the analysis on fully complete data provides a useful sensitivity
analysis. Missing data were imputed using the mice package in R (multiple imputation by chained
equations; http://cran.r-project.org/web/packages/mice/) and pooled estimates35 of model parameters
based on 50 data imputations were obtained for the mixed-effects regression models reported in Table 9.
The pooled estimates of the treatment group effect were –1.2 (95% CI –4.2 to 1.9) for the PRWE and
–3.2 (95% CI –6.2 to –0.1) for the DASH questionnaire scores, with the percentage of the variability
attributable to the uncertainty caused by the missing data estimated at 5.8% and 5.5% for the two
outcome measures respectively. In summary, the inferences based on the complete data, after imputation,
are not markedly different from those reported from the complete case analysis in Table 18.
TABLE 18 Data completeness for the PRWE questionnaire at 12 months by age group and sex
Age (years) Sex Data, n Missing, n Total, n % data missing
< 50 Female 73 8 81 9.9
Male 28 11 39 28.2
≥ 50 Female 281 23 304 7.6
Male 33 4 37 10.8
Total 415 46 461 10.0
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Complications
Complications were reported by participants at the 6-week follow-up assessment, and also at any point
during the first 12 months of follow-up using the study adverse event reporting procedures. Table 21
shows numbers of patients reporting complications by treatment group.
There was no evidence to suggest that rates for any of the reported complications (e.g. wound infections)
differed between treatment groups, based on comparing counts in groups using Fisher’s exact test. The
proportion of participants given a cast after the operation differed between treatment groups, as expected,
as did, consequently, the number of plaster changes required.
TABLE 21 Complications based on patient-reported events at the 6-week assessment and adverse events within
12 months of operation
Complication
K-wire (n= 230) Locking plate (n= 231)
p-valueaNo, n Yes, n No, n Yes, n
Cast and dressing
Cast after operation 5 224 57 171 < 0.001
Dressing change 215 12 219 11 0.834
Plaster change 187 42 211 17 0.001
Postoperative complications
Refracture 225 2 226 2 1.000
Neurological injury 215 14 210 20 0.373
Vascular injury 229 0 228 0 1.000
Tendon injury 225 4 223 6 0.751
Superficial wound infection 209 18 216 12 0.264
Deep wound infection 226 1 227 1 1.000
Treatment
Antibiotics 217 13 220 11 0.682
Removal of metalwork 223 7 220 11 0.472
Debridement 228 2 230 1 0.623
Revision 222 5 226 2 0.285
a Fisher’s exact test.
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Chapter 4 Results of economic analysis
Introduction
The health economics analysis was designed to provide an economic evaluation of distal radial fractures
treated by volar locking-plate fixation compared with K-wire fixation. The aim was to assess the
cost-effectiveness of distal radial fractures treated by volar locking-plate fixation versus K-wire fixation
from the NHS perspective. A societal perspective for costs was adopted for sensitivity analysis.
Unit cost data
Unit cost of resource use
Individual-level resource use was combined with unit costs to calculate the total health-care use cost for
each patient. In order to convert resource usage figures into costs, unit cost figures were assigned from
national databases such as the PSSRU Costs of Health and Social Care 201234 and the Department of
Health’s National Schedule of Reference Costs.39 Further inpatient care following the initial operation was
costed as Minimal Elbow and Lower Arm Procedures for Non-Trauma (HRG codes HB79Z and HB73Z)
except if surgical hand complications such as metal removal or debridement were reported at 6-week
follow-up, where inpatient stay was costed as Minor Elbow and Lower Arm Procedures for Trauma
(HRG codes HA73B and HAB73C). All costs were adjusted to 2012 prices using the Campbell and
Cochrane Economics Methods Group and Evidence for Policy and Practice Information and Coordinating
Centre Cost Converter.40 Table 22 presents the summary of unit costs.
TABLE 22 Summary of patient-reported health-care use and associated unit costs
Item Unit cost (£) Source
Initial operation
Cost for average distal fracture
surgery (≥ 19 years)
1983.39 National schedule of reference costs year 2011–2012 – Minor Elbow
and Lower Arm Procedures for Trauma – HA73C39
Day case 1375.34 National schedule of reference costs year 2011–2012 – Minor Elbow
and Lower Arm Procedures for Trauma – HA73C39
Adjustment per day± average LOS
(≥ 19 years)
278.07 National schedule of reference costs year 2011–2012 – Elective
Inpatient Excess day – HA73C39
Average LOS for distal fracture 0.95 days Trial data
VLP: average LOS 0.98 days Trial data, t-test, p= 0.696
K-wire: average LOS 0.92 days Trial data
Average surgery time 53.57
minutes
Trial data
VLP: average surgery time 70.00
minutes
Trial data, t-test, p= 0.000
K-wire: average surgery time 37.18
minutes
Trial data
VLP: implant+ consumables 818.26 UHCW
K-wires: implant+ consumables 54.23 UHCW
continued
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TABLE 22 Summary of patient-reported health-care use and associated unit costs (continued )
Item Unit cost (£) Source
Subsequent inpatient care
Inpatient (orthopaedics – wrist/arm)
Cost for average LOS 2064.71 National schedule of reference costs year 2011–2012 – HB79Z39
Day case 692.04 National schedule of reference costs year 2011–2012 – HB79Z39
Adjustment per day± average LOS 302.01 National schedule of reference costs year 2011–2012 – HB73Z39
Inpatient (orthopaedics – other bones)
Cost for average LOS 3556.04 National schedule of reference costs year 2011–2012 – HB99Z39
Day case 928.36 National schedule of reference costs year 2011–2012 – HB99Z39
Adjustment per day± average LOS 293.08 National schedule of reference costs year 2011–2012 – HB99Z39
Inpatient (other non-surgery)
Cost for average LOS 2688.10 National schedule of reference costs year 2011–2012 – HB91Z39
Day case 602.61 National schedule of reference costs year 2011–2012 – HB91Z39
Adjustment per day± average LOS 261.21 National schedule of reference costs year 2011–2012 – HB91Z39
Inpatient (other)
Rehabilitation unit 985.00 PSSRU 2012, p. 114, weekly service costs per bed34
Outpatient care
Orthopaedicsa 103.72 National schedule of reference costs year 2011–2012 – 110T39
Pathologyb (for blood tests) 60.74 National schedule of reference costs year 2011–2012 – 82239
Radiology (for radiographs,
per event)
153.21 National schedule of reference costs year 2011–2012 – 81139
Physiotherapy (per session) 40.70 National schedule of reference costs year 2011–2012 – 65039
Primary and community care
GP surgery visit 40.00 PSSRU 2012, pp. 182–3, £3.40 per minute, average 11.7 minutes
per visit34
GP clinic visit 58.00 PSSRU 2012, pp. 182–3, £4.3 per minute, 17.2 minutes per visit34
GP home visit 101.00 PSSRU 2012, pp. 182–3, £258 per hour, average 23.4 minutes per visit 34
GP phone contact 24.00 PSSRU 2012, pp. 182–3, 7.1 minutes per contact34
Practice nurse surgery visit 11.63 PSSRU 2012, pp. 180–1, £45 per hour, average 15.5 minutes per visit34
Practice nurse home visit 18.75 PSSRU 2012, pp. 180–1, £45 per hour, average 25 minutes per visit34
Practice nurse phone contact 3.50 PSSRU 2012, pp. 180–1, £35 per hour, average 6 minutes per visit34
District nurse surgery visit 10.85 PSSRU 2012, p. 175, £42 per hour, average 15.5 minutes per visit34
District nurse home visit 21.83 PSSRU 2012, p. 175, £61 per hour, average 20 minutes per visit34
District nurse phone contact 4.20 PSSRU 2012, p. 175, £42 per hour, average 6 minutes per visit34
Physiotherapist surgery visit 15.00 PSSRU 2012, p. 167, £30 per hour, average 30 minutes per visit34
Physiotherapist home visit 44.16 PSSRU 2010, p. 151, £39 per hour, average 60 minutes per visit, inflated
Occupational therapist surgery visit 15.00 PSSRU 2012, p. 167, £30 per hour, average 30 minutes per visit34
Occupational therapist home visit 44.16 PSSRU 2010, p. 151, £39 per hour, average 60 minutes per visit34
GP, general practitioner; LOS, length of stay; VLP, volar locking plate.
a This includes seeing a surgeon.
b This is the standardised cost per event including the costs of activities relating to pathology testing; an average of
10 units of pathology testing can be required in each event.
RESULTS OF ECONOMIC ANALYSIS
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Unit cost of medications
Unit costs for medications were obtained from the BNF No. 67 (September 2013)41 and the NHS Electronic
Drug Tariff (October 2013).42 Patients reported details for medications that were taken within the three
budgetary periods (discharge to 3 months, 3–6 months, 6–12 months), including the quantity taken per
day and the number of days. We calculated the total medication costs using the average cost per dose for
each product and the mean quantity taken per day during the reported number of days. Where a dose
range reported ‘as required’, we included the cost of one box of the drug. We assumed that all
medications were in tablet form unless stated. If the dose of the drug was not recorded, we assumed the
patient received the same dosage as other patients who reported the same drugs. If the quantity was
not recorded, we applied the average quantity for that drug as reported in the data. Table 23 shows all
the unit costs for the drugs that were reported in the trial.
TABLE 23 Summary of patient-reported medication use and associated unit costs
Item Unit cost (£)a Source
Alendronic acid 1.44 10mg (from pack of 28)
Alendronic acid 1.10 70mg (from pack of 4)
Amitriptyline 0.84 10mg (from pack of 28)
Amitriptyline 0.83 25mg (from pack of 28)
Amoxicillin 0.95 250mg (from pack of 21)
Aspirin 0.76 75mg (from pack of 28)
Atenolol 0.83 100mg (from pack of 28)
Atorvastatin 1.89 10ml (from pack of 28)
Bendroflumethiazide 0.81 2.5mg (from pack of 1)
Bisoprolol 1.02 5mg (from pack of 28)
Calcium carbonate chewable 9.33 (From pack of 100)
Calcium salts (ADCAL®, ProStrakan) 7.25 (From pack of 100)
Calcium salts (Cacit®, Warner Chilcott) 11.81 (From pack of 76)
Citalopram 1.31 10mg (from pack of 28)
Clarithromycin 2.52 250mg (from pack of 14)
Co-amoxiclav 2.34 250mg (from pack)
Cocodamol 3.54 30mg (from pack of 100)
Cocodamol (Solphadol®, Sanofi-Aventis) 6.74 (From pack of 100)
Codeine 2.26 30mg (from pack of 30)
Co-dydramol 1.06 500mg (from pack of 30)
Cholecalciferol (ADCAL-D3®, ProStrakan) 3.84 1500mg (from pack of 56)
Cholecalciferol (Calceos®, Innotech International) 3.62 (From pack of 60)
Cholecalciferol (Calcichew-D3®, Takeda) 4.24 (From pack of 60)
Cholecalciferol (Calfovit D3®, Menarini) 4.32 (From pack of 30)
Cholecalciferol (Fultium®, Internis) 8.44 (From pack of 84)
Diclofenac 1.42 50mg (from pack of 84)
Diclofenac (Voltarol®, Novartis) 3.46 25mg (from pack of 30)
Dihydrocodeine 5.18 60mg (from pack of 56)
Enalapril maleate 0.95 10mg (from pack of 28)
continued
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TABLE 23 Summary of patient-reported medication use and associated unit costs (continued )
Item Unit cost (£)a Source
Ergocalciferol 30.34 1.25mg (from pack of 50,000)
Esomeprazole (Nextum®, AstraZeneca) 25.19 40mg (from pack of 28)
Eye drops 2.80 (From pack of 10)
Ferrous sulphate 1.01 (From pack of 28)
Flucloxacillin 1.77 250mg (from pack of 1)
Flucloxacillin 2.89 500mg (from pack of 28)
Furosemide 0.80 20mg (from pack of 28)
Ibuprofen 1.44 200mg (from pack of 84)
Ibuprofen 1.73 400mg (from pack of 84)
Ibuprofen (gel) 2.13 50 g (from pack of 1)
Lansoprazole (Prevacid®, Takeda) 1.20 15mg (from pack of 28)
Lercanidipine 4.98 10mg (from pack of 28)
Meloxicam 1.54 15mg (from pack of 30)
Meptazinol (Meptid®, Almirall Ltd) 22.11 200mg (from pack of 112)
Mirtazapine 3.08 15mg (from pack of 28)
Morphine 11.21 10mg (from pack of 1)
Morphine salts (Oramorph®, Boehringer Ingelheim) 1.78 10mg (from pack of 100)
Naproxen 1.25 250mg (from pack of 28)
Naproxen 1.65 500mg (from pack of 28)
Nefopam 10.54 30mg (from pack of 90)
Nefopam hydrochloride (Acupan®, iNova Pharmaceuticals) 10.54 30mg (from pack of 90)
Nifedipine (Adalat®, Bayer) 7.23 5mg (from pack of 84)
Olanzapine 1.17 2.5mg (from pack of 28)
Omeprazole 1.62 10mg/20mg (from pack of 28)
Oxycodone 8.70 5ml (from pack of 50)
Oxycodone hydrochloride (OxyContin®, Purdue Pharma) 49.82 20mg (from pack of 56)
Oxycodone hydrochloride (OxyContin®, Purdue Pharma) 74.81 30mg (from pack of 56)
Paracetamol 0.16 500mg (from pack of 16)
Polymyxins (Polyfax®, TEVA UK) 3.26 4 g (from pack of 1)
Pregabalin 2.77 400mg (from pack of 84)
Risedronate 19.12 35mg (from pack of 4)
Ramipril (capsules) 1.39 10mg (from pack of 28)
Strontium ranelate (Protelos®, Servier) 25.60 2 g (from pack of 28)
Tibolone (Livial®, Merck Sharp and Dohme) 10.36 2.5mg (from pack of 28)
Tamoxifen 5.71 10mg (from pack of 30)
Tramadol 1.14 50mg (from pack of 30)
Venlafaxine (Efexor®, Effexor® and Trevilor®, Pfizer) 2.62 37.5mg (from pack of 56)
Topical NSAIDs (Voltarol Emulgel®, Novartis) 1.55 (From pack of 20)
Zopiclone 1.30 (From pack of 28)
a It is defined as the cost of a given package of a product.
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Unit cost of aids and adaptations
Patients reported any equipment that they had used to protect their injury or make their daily life easier to
manage and the number of those. A number of aids and adaption tools were suggested and patients
could add other equipment that was not in the list. Unit costs for aids and adaptations were taken from
the website MobilitySmart (www.mobilitysmart.cc/), accessed in October 2013, which supplies the NHS
and the PSSRU Costs of Health and Social Care 2012.34 We calculated the total aids costs using the
number of aids and the cost for each product. If the quantity was not recorded, we applied the average
quantity for that aid as reported in the data. Reported aids and adaptations and unit prices are available in
Table 24. Those costs were incurred by the NHS.
Intervention costs
The initial fixation surgery cost was based on the initial hospital stay and the operative cost (see Table 22).
The cost of the initial distal radial fracture fixation surgery was assessed using NHS reference costs and
HRG code HA73B (Minor Elbow and Lower Arm Procedures for Trauma). Costs for the initial operative
period were identified for each patient using the average length of stay as reported in the patient records
for the primary surgery. They were assumed to be £1375.34 for a day case or £1983.39 for overnight
admission. We used excess bed-day costs when patient experience a length of stay beyond the average
length of stay reported. For example, the cost to NHS was £1375.34 if a patient was discharged the same
day, £1983.39 if the patient was referred to overnight hospital care at least one night but no more than
the average length of stay; extra bed-day costs (based on a bed-day cost of £278.07) were added if a
patient stayed more than the average length of stay. This cost was taken to include all expenditures
incurred prior to discharge, including any items provided to patients before departure.
The operative costs for both volar locking-plate and K-wire fixations were provided by UHCW finance
department; these included implant costs and consumables and are reported in Table 25.
The total cost of each arm of the trial was calculated combining the resource use and unit cost data along
with the initial surgery cost.
Societal costs
Costs from the societal perspective were calculated by combining productivity loss and loss of earnings
due to work absence, private costs such as treatments within private settings and out-of-pocket expenses
incurred as a result of the wrist surgery, and reported use of Personal Social Services related to the
treatment. We assumed that the Personal Social Services costs were unlikely to be directly supported by
the NHS and this is why they were included in the societal perspective sensitivity analysis.
TABLE 24 Summary of patient-reported aids and adaptation equipment use and associated unit costs
Item Unit cost (£) Source
Wrist brace/splint 10.00 MobilitySmart
Grab rail 95.00 PSSRU 2012, p. 111, average total cost34
Dressing aids 5.95 MobilitySmart
Long-handle shoe horns 3.98 MobilitySmart
Bathing aids 23.35 MobilitySmart
Kitchen aids (jar/tin openers, etc.) 21.44 MobilitySmart
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TABLE 25 Summary of the initial surgery theatre cost including consumables and prosthetic devices
Description of item Code of item Quantity used Unit price (£) Cost (£)
K-wire
Reinforced gown XL 95224 2 3.74 7.48
Surgical visor masks 48247 2 1.01 2.03
Theatre masks 48100 2 0.06 0.11
Gammex gloves 351143 1 0.68 0.68
Biogel gloves 96180 2 1.14 2.28
Non-sterile gloves 8801 5 0.02 0.11
Image intensifier cover 39.00.02 3 2.49 7.47
Laceration pack RMT9150 1 13.24 13.24
Surface wipes CMW01X 6 0.03 0.18
Black bag 1 0.06 0.06
Yellow bag UN3291 2 0.05 0.11
Polythene bag for extras 1 0.02 0.02
Inco pad 200995 2 0.13 0.26
K-wire OS292160 3 2.94 8.82
Sterilisation of drill TSU 1 10.00 10.00
Ethicon sutures w319 1 1.22 1.22
Mepore 9 × 10 cm r33334 1 0.16 0.16
Total for equipment used for K-wire surgery 54.23
Volar locking plate
Surgical visor masks 48247 3 1.01 3.04
Theatre masks 48100 2 0.06 0.11
Gammex gloves 351143 1 0.68 0.68
Biogel gloves 96180 3 1.14 3.42
Non-sterile gloves 8801 6 0.02 0.14
Image intensifier cover 39.00.02 3 2.49 7.47
Upper limb pack RMT9150 1 12.40 12.40
Surface wipes CMW01X 6 0.03 0.18
Black bag 1 0.06 0.06
Yellow bag UN3291 2 0.05 0.11
Polythene bag for extras 1 0.02 0.02
Inco pad 200995 2 0.13 0.26
Distal volar radius plate DVRAW(L/R) 1 384.00 384.00
Shaft screws CS(14) 3 27.00 81.00
Bar screws FP(12) 6 44.00 264.00
Ethicon sutures w319 1 1.22 1.22
Mepore 9 × 10 cm r33334 1 0.16 0.16
Sterilisation of basic set TSU 1 20.00 20.00
Sterilisation of drill TSU 2 10.00 20.00
Sterilisation of distal volar radius set TSU 1 20.00 20.00
Total for equipment used for volar locking plate surgery 818.26
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Personal social services included number of weeks of frozen/hot meals on wheels, laundry services per
load, and number of visits of carers and social workers. Unit costs were assigned using PSSRU and
Information Centre of Personal Social Services in councils; they are reported in Table 26.
Patients reported their time off work in days or in terms of lost income because of their wrist fracture at
every collection point. We employed a human capital approach using the gross median weekly pay rate for
full-time employees from the Office for National Statistics (£506, April 2012)44 and divided this by 5 to
generate the cost of lost productivity per day.
Utility and quality-adjusted life-years
Patient health-related quality of life was assessed using the EQ-5D,43 which was included along with
the patient resource-use questionnaires. Changes in EQ-5D scores at baseline, 3 months, 6 months and
12 months were evaluated using two-sample t-tests to explore any important differences in these end
points within the time frame of the trial. They are useful to understand the impact of the length of the
follow-up on repeated measurements of the health outcome in which insufficiently long follow-up periods
may potentially introduce biases in the subsequent cost-effectiveness analysis.
In line with the NICE reference case,33 the primary outcome for the economic evaluation was QALY.
Patient responses to the EQ-5D questionnaire at each time point were converted to QALYs using the
standard UK tariff values45 and an area under the curve approach. QALYs were calculated by multiplying
these values with the time spent in each state, with quality of life linearly interpolated for the periods
between the four observations provided in the trial data. QALYs represent a quality-weighted survival value
in which 1 QALY is the equivalent of 1 year of full health. Average QALYs between adjacent time points
were calculated to generate smoothed estimates between those time points.
Missing data
We calculated the mean total costs per patient from a NHS perspective adding the cost of inpatient stay,
outpatient visit, consultations, medication, equipment, and applicable intervention costs for all patients
where response data were available. Respondents who fail to complete individual items of the EQ-5D
are not allocated a utility index score. From the overall sample, missing data represented 7.07%.
Importantly, the health economics criteria for inclusion were slightly more restrictive than those for the
statistical analysis. The complete data analysis was based on 278 patients.
For those cases in which neither resource usage nor quality-of-life data were available, these figures could
not be calculated. We addressed missingness using two alternative methods.
TABLE 26 Summary of the reported personal social services and private costs and associated unit costs
Item Unit cost (£) Source
Personal social services
Frozen meals on wheels (weekly) 41.40 Lewisham council, adult social care
Hot meals on wheels (weekly) 46.00 PSSRU 2012, p. 12534
Laundry services (per load) 4.30 North Yorkshire social care
Care workers/help at home (per visit) 18.00 PSSRU 2012, p. 193 per weekday hour34
Social workers (per visit) 39.00 PSSRU 2012, p. 190 per hour34
Cost of lost productivity
Days off work (per day) 101.20 Office for National Statistics – April 2012, median
grossly week earning for full-time employees £50644
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We initially used the LOCF approach. Costs and EQ-5D values were carried forward for only one successive
missing observation. Patients with more than one consecutive missing observation were omitted from the
analyses. Observations were not carried backwards. The LOCF imputation analysis was then conducted
on a sample of 367 patients. The advantage of the LOCF method is that it minimises the number of
subjects who are eliminated from the analysis. However, the LOCF method has also been found to give a
biased estimate of the treatment effect and underestimate the variability of the estimated result.46,47
We then used multiple imputations via chained equations35,36 to complete missing data assuming missing
at random and using Stata 12 (StataCorp LP, College Station, TX, USA). Missing cost data were predicted
in terms of QALYs, treatment received, length of stay, age, gender, job status, patient’s self-reported
health status, PRWE questionnaire score and DASH questionnaire score. Missing QALY data were predicted
in terms of this same list (excluding QALYs), plus each of the cost items. In order to remove implausible
data, missing cost data were constrained to be positive. A total of 10 imputations were created to stabilise
the result. The reported cost-effectiveness results were synthesised based on all imputed data sets.
Cost-effectiveness analysis
Our analysis was a cost–utility analysis over 12 months examining the cost per QALY gained for all
patients. We initially undertook descriptive statistics of costs and EQ-5D scores and conducted parametric
tests (Students’ t-tests and ANOVA tests) to evaluate any important differences in the end points
within the time frame of the trial. We then calculated ICERs by dividing the average difference in cost
between the two arms by the average difference in QALYs between the two arms.
We also present cost-effectiveness scatter plots illustrating the uncertainty surrounding the cost-effectiveness
estimates. The cost-effectiveness planes were derived using bootstrapping with replacement.
Sensitivity analyses were conducted to explore the impact of costs and missing data on the study results.
First, the influence of outliers was evaluated; for this, participants with very large NHS health-care expenses
were excluded from the analysis. These outliers may have a large effect on the mean cost and lead to
different cost-effectiveness analysis results. Therefore, it is important, especially for policy-makers, to
produce extreme scenarios to capture the worse and best cases. To evaluate the impact of missing data,
the complete case analysis was conducted including only those participants with no missing data. The
results of this analysis were compared with the results obtained through imputation using LOCF and then
multiple imputations. We undertook the same analysis using costs from the societal perspective; this
perspective includes the costs of use of personal social services, cost of lost productivity and private
expenses in addition to the NHS costs. Finally, we carried out an adjusted analysis. To be consistent with
the clinical analysis, we evaluated the cost-effectiveness by adjusting a set of characteristics at baseline
such as gender, age, PRWE questionnaire score and DASH questionnaire score. Baseline EQ-5D score was
also added to account for any possible baseline imbalance and to improve the precision of the estimates.
Cost-effectiveness results
Resource use and QALY data were available for 278 patients, with 137 patients receiving volar
locking-plate fixation and 141 patients receiving K-wire fixation.
Health-care resource use
Table 27 presents the details of health-care resource used over the 12 months after discharge for complete
case data. Resource use is broadly comparable between the two treatments. Patients were frequent users
of physiotherapy outpatient visits (6.9 visits over the 12 months) and reported on average 3.6 radiology
visits and 3.6 visits in orthopaedics outpatient visits. Use of general practitioner (GP) visits and nurse visits
was infrequent. Patients reported using a wrist brace or splint. In terms of medications, we note that
paracetamol tablets were the most reported medications in the questionnaires. No significant differences
were observed between the two groups. Patients receiving K-wires appear to have used more bathing
aids than patients receiving volar locking plates at a 10% significance level (p= 0.087).
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TABLE 27 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete case)
Item Dose
Mean usage (SD)
Difference:
p-value of
t-testK-wire (n= 141)
Volar locking
plate (n= 137)
Subsequent inpatient care
Orthopaedics (wrist, arm, other bones) – 0.383 (1.252) 0.343 (1.320) 0.796
Rehabilitation unit – 0.007 (0.084) 0 0.325
Other surgery – 0.170 (0.845) 0.117 (0.385) 0.500
Outpatient care
Orthopaedics – 3.340 (4.063) 3.788 (4.633) 0.392
Pathology – 0.298 (1.423) 0.358 (1.464) 0.730
Radiology – 1.801 (2.723) 2.197 (2.695) 0.225
Physiotherapy – 6.128 (8.255) 7.584 (11.212) 0.218
Primary and community care
In surgery
GP – 0.766 (2.144) 0.555 (1.212) 0.315
Practice nurse – 0.113 (0.549) 0.080 (0.322) 0.541
Physiotherapist – 0.879 (2.126) 0.854 (4.420) 0.951
Occupational therapist – 0.071 (0.408) 0.088 (1.025) 0.858
In clinic
GP – 0 0.029 (0.241) 0.151
Practice nurse – 0 0.007 (0.085) 0.311
District nurse – 0 0
Physiotherapist – 0.241 (0.940) 0.409 (2.102) 0.389
Occupational therapist 0.014 (0.168) 0.051 (0.426) 0.340
At home
Practice nurse – 0.007 (0.084) 0 0.325
Physiotherapist – 0.014 (0.168) 0 0.325
Occupational therapist – 0.071 (0.842) 0 0.325
Aids and adaptation
Wrist brace/splint – 0.780 (1.076) 0.964 (1.239) 0.188
Grab rail – 0.078 (0.464) 0.029 (0.270) 0.286
Dressing aids – 0.071 (0.425) 0.109 (0.649) 0.557
Long-handle shoe horns – 0.014 (0.168) 0.007 (0.085) 0.669
Bathing aids – 0.021 (0.145) 0 0.087
Kitchen aids (jar/tin openers, etc.) – 0.078 (0.687) 0.066 (0.406) 0.856
Medications
Alendronic acid 10mg 0.043 (0.235) 0.022 (0.147) 0.382
Alendronic acid 70mg 0.220 (1.043) 0.0451 (0.3900) 0.077
continued
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TABLE 27 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete case) (continued )
Item Dose
Mean usage (SD)
Difference:
p-value of
t-testK-wire (n= 141)
Volar locking
plate (n= 137)
Amitriptyline 10mg 0.064 (0.600) 0.058 (0.683) 0.944
Amitriptyline 25mg 0 0.029 (0.241) 0.151
Amoxicillin 250mg 0 0.022 (0.256) 0.311
Aspirin 75mg 0.028 (0.337) 0.073 (0.703) 0.499
Atenolol 100mg 0 0.029 (0.342) 0.311
Atorvastatin 10ml 0.028 (0.337) 0 0.325
Bendroflumethiazide 2.5mg 0 0.657 (7.689) 0.311
Bisoprolol 5mg 0.028 (0.337) 0 0.325
Calcium carbonate chewable – 0.028 (0.205) 0.015 (0.171) 0.544
Calcium salts (ADCAL®, ProStrakan) – 0.028 (0.205) 0.007 (0.085) 0.267
Calcium salts (Cacit®, Warner Chilcott) – 0 0.007 (0.085) 0.311
Cholecalciferol (ADCAL-D3®, ProStrakan) 1500mg 0.064 (0.418) 0.058 (0.482) 0.920
Cholecalciferol (Calceos®, Innotech International) – 0.043 (0.376) 0.036 (0.307) 0.883
Cholecalciferol (Calcichew-D3®, Takeda) – 0.035 (0.421) 0.066 (0.571) 0.615
Cholecalciferol (Calfovit D3®, Menarini) – 0.007 (0.084) 0 0.325
Cholecalciferol (Fultium®, Internis) – 0.014 (0.168) 0 0.325
Citalopram 10mg 0.028 (0.337) 0 0.325
Clarithromycin 250mg 0.007 (0.084) 0 0.325
Co-amoxiclav 250mg 0 0.022 (0.256) 0.311
Cocodamol 30mg 0.142 (0.661) 0.095 (0.541) 0.518
Cocodamol (Solphadol®, Sanofi-Aventis) – 0 0.022 (0.256) 0.311
Codeine 30mg 0.652 (3.408) 0.234 (1.208) 0.176
Co-dydramol 500mg 0 0.044 (0.361) 0.151
Diclofenac 50mg 0.043 (0.313) 0.051 (0.390) 0.840
Diclofenac (Voltarol®, Novartis) 25mg 0 0.029 (0.208) 0.097
Dihydrocodeine 60mg 0.121 (1.143) 0.095 (1.111) 0.850
Enalapril maleate 10mg 0.007 (0.084) 0 0.325
Ergocalciferol 1.25mg 0.007 (0.084) 0 0.325
Esomeprazole (Nextum®, AstraZeneca) 40mg 0 0.029 (0.342) 0.311
Eye drops – 0.128 (1.516) 0 0.325
Ferrous sulphate – 0 1.020 (0.851) 0.155
Flucloxacillin 250mg 0.794 (9.432) 0 0.325
Flucloxacillin 500mg 0.014 (0.168) 0.015 (0.171) 0.984
Furosemide 20mg 0.028 (0.337) 0 0.325
Ibuprofen 200mg 0.092 (0.477) 0.102 (0.633) 0.882
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TABLE 27 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete case) (continued )
Item Dose
Mean usage (SD)
Difference:
p-value of
t-testK-wire (n= 141)
Volar locking
plate (n= 137)
Ibuprofen 400mg 0.007 (0.084) 0.022 (0.190) 0.400
Ibuprofen (gel) 50 g 0.007 (0.084) 0 0.325
Lactulose 300ml 0 1.314 (15.378) 0.311
Lansoprazole (Prevacid®, Takeda) 15mg 0 0.029 (0.342) 0.311
Lercanidipine 10mg 0 0.029 (0.342) 0.311
Meloxicam 15mg 0 0.022 (0.256) 0.311
Meptazinol (Meptid®, Almirall Ltd) 200mg 0 0.007 (0.085) 0.311
Mirtazapine 15mg 0.014 (0.168) 0.029 (0.342) 0.641
Morphine 10mg 0.397 (4.716) 0.044 (0.513) 0.384
Morphine salts (Oramorph®,
Boehringer Ingelheim)
10mg 0 0.007 (0.085) 0.311
Naproxen 250mg 0.014 (0.168) 0.015 (0.171) 0.984
Naproxen 500mg 0 0.015 (0.171) 0.311
Nefopam 30mg 0 0.015 (0.171) 0.311
Nefopam hydrochloride (Acupan®,
iNova Pharmaceuticals)
30mg 0.007 (0.084) 0 0.325
Olanzapine 2.5mg 0 0.029 (0.342) 0.311
Omeprazole 10mg 0.007 (0.084) 0.029 (0.342) 0.457
Omeprazole 20mg 0.035 (0.347) 0.029 (0.342) 0.880
Oxycodone 5ml 0 0.007 (0.085) 0.311
Oxycodone hydrochloride (OxyContin®,
Purdue Pharma)
20mg 0.028 (0.337) 0 0.325
Oxycodone hydrochloride (OxyContin®,
Purdue Pharma)
30mg 0.028 (0.337) 0 0.325
Paracetamol 500mg 2.702 (10.11) 1.285 (4.618) 0.136
Polymyxins (Polyfax®, TEVA UK) 4 g 0.298 (3.537) 0 0.325
Risedronate 35mg 0.028 (0.337) 0.058 (0.482) 0.546
Ramipril (capsules) 10mg 0 0.029 (0.240) 0.311
Strontium ranelate (Protelos®, Servier) 2 g 0 0.029 (0.342) 0.311
Tibolone (Livial®, Merck Sharp and Dohme) 2.5mg 0.043 (0.505) 0 0.311
Tamoxifen 10mg 0 0.022 (0.180) 0.311
Tramadol 50mg 0.262 (1.850) 0.212 (1.160) 0.785
Zopiclone – 0 0.007 (0.085) 0.311
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Costs
The total costs associated with resource use during the trial among complete case data are shown in
Table 28. The mean total NHS resource use costs are £3385 for K-wires and £4288 for volar locking plates
and were significantly higher for volar locking plates (by £903). Lost earnings and productivity losses to
employers through sickness absences appeared higher in the K-wire arm, but the difference does not
appear to be significant. Overall, societal costs are on average £48 higher in the K-wire arm. However,
there were no significant differences in NHS resource use costs and societal costs between the treatment
arms according to the t-tests.
TABLE 28 Costs of resources used in relation to distal fracture fixation by treatment arms (not imputed)
Item Parameter K-wire (n= 141)
Volar locking
plate (n= 137)
Difference: p-value
of t-test
NHS resource use costs (£)a Mean (SD) 3384.78 (2097.09) 4287.89 (2244.30)
Incremental (SE) 903.41 (260.43) < 0.001
Social care costs (£) Mean (SD) 13.01 (105.37) 8.18 (57.97)
Incremental (SE) –4.83 (10.24) 0.637
Private cost (£) Mean (SD) 22.74 (123.57) 30.22 (158.78)
Incremental (SE) 7.48 (17.04) 0.372
Cost of lost productivity (£) Mean (SD) 436.51 (1876.50) 316.06 (1481.78)
Incremental (SE) –120.44 (203.16) 0.405
Societal costs (£, includes all
the previous cost categories)
Mean (SD) 1984.10 (2679.43) 1936.48 (3299.80)
Incremental (SE) –47.63 (360.04) 0.828
SE, standard error.
a The costs also include implant costs and initial surgery costs.
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Health outcomes
Table 29 details the EQ-5D scores at pre injury, baseline, 3 months, 6 months and 12 months in complete
case data and when missing values are imputed. Both groups showed increasing EQ-5D scores from
baseline to the last follow-up point; the most important increase is observed between baseline and
3-month follow-up point for both treatments, doubling the baseline EQ-5D score. It is noted that patients
at 12 months have not recovered an EQ-5D score equivalent to their pre-injury, retrospectively reported,
EQ-5D score.
On average, patients receiving a volar locking plate had higher EQ-5D index scores at baseline and at each
follow-up point, but independent-sample t-tests indicated that the changes in EQ-5D score over time were
not statistically significant. The average total number of QALYs over the 12 months was marginally higher
in the volar locking-plate arm (0.745) than in the K-wire arm (0.731). Tables 30 and 31 provide the mean
EQ-5D change scores between pre-injury and the follow-up points for the LOCF imputed analysis and
multiple imputed data respectively. The same comments applied to the EQ-5D scores. The statistical tests
indicated that there were no significant differences between EQ-5D scores at baseline for the two
treatment arms, and, for this reason, adjustments on EQ-5D at baseline were not required.
TABLE 29 Mean EQ-5D index scores at the baseline and follow-up points and annual QALYs of distal fracture
fixation by treatment arms (complete case data)
Time point Parameter
K-wire
(n= 141)
Volar locking
plate (n= 137)
Difference:
p-value of t-test
Retrospective pre injury Mean (SD) 0.928 (0.170) 0.947 (0.149)
Incremental (SE) 0.019 (0.019) 0.320
Baseline Mean (SD) 0.354 (0.303) 0.373 (0.317)
Incremental (SE) 0.019 (0.037) 0.611
3 months Mean (SD) 0.725 (0.210) 0.739 (0.224)
Incremental (SE) 0.014 (0.026) 0.591
6 months Mean (SD) 0.787 (0.193) 0.807 (0.183)
Incremental (SE) 0.020 (0.023) 0.366
12 months Mean (SD) 0.842 (0.188) 0.845 (0.184)
Incremental (SE) 0.002 (0.022) 0.918
Total QALYs Mean (SD) 0.731 (0.173) 0.745 (0.162)
Incremental (SE) 0.014 (0.020) 0.484
SE, standard error.
DOI: 10.3310/hta19170 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 17
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
Cost-effectiveness results within the NHS perspective
Table 32 shows the total costs and QALY gains for each of the treatment arms. The differences in QALY
gains between groups, 0.008 QALYs, were minimal and suggested only small health benefits of volar
locking plates over K-wires. The volar locking-plate group had the highest QALY gains over the trial period.
The mean total costs were higher for the volar locking-plate group; the high SD for the cost estimates
indicates the presence of a few outlying individuals who incurred significant health service costs.
Table 33 provides the cost-effectiveness results, showing the incremental costs and benefits as well as the
ICER. Interpretation should be tempered by considering the small between-group differences in QALY
gains and the high level of uncertainty surrounding the QALY estimates. The results suggest that volar
locking plates were more expensive than K-wires, with an incremental cost of £726.46, and had higher,
albeit small, QALY gains.
TABLE 30 Index scores for EQ-5D at the baseline and follow-up points and annual QALYs of distal fracture fixation
by treatment arms (LOCF imputed data)
Time point Parameter
K-wire
(n= 187)
Volar locking
plate (n= 180)
Difference:
p-value of t-test
Retrospective pre injury Mean (SD) 0.918 (0.176) 0.942 (0.142)
Incremental (SE) 0.024 (0.009) 0.149
Baseline Mean (SD) 0.358 (0.307) 0.373 (0.323)
Incremental (SE) 0.015 (0.033) 0.641
3 months Mean (SD) 0.714 (0.219) 0.722 (0.242)
Incremental (SE) 0.008 (0.024) 0.747
6 months Mean (SD) 0.768 (0.216) 0.794 (0.195)
Incremental (SE) 0.026 (0.022) 0.225
12 months Mean (SD) 0.824 (0.209) 0.841 (0.189)
Incremental (SE) 0.017 (0.021) 0.411
Total QALYs Mean (SD) 0.717 (0.187) 0.735 (0.177)
Incremental (SE) 0.018 (0.019) 0.345
SE, standard error.
TABLE 31 Index scores for EQ-5D at the baseline and annual QALYs of distal fracture fixation by treatment arms
(multiple imputed data)
Time point Parameter
K-wire
(n= 230)
Volar locking
plate (n= 230)
Difference:
p-value of t-testa
Retrospective pre injury Mean (SD) 0.919 (0.169) 0.936 (0.154)
Incremental (SE) 0.075 (0.005) 0.259
Baseline Mean (SD) 0.358 (0.305) 0.363 (0.323)
Incremental (SE) 0.070 (0.009) 0.856
Total QALYs Mean (SD) 0.734 (0.167) 0.742 (0.160)
Incremental (SE) 0.013 (0.005) 0.649
SE, standard error.
a The t-test reported for treatment is the multiple imputation version for the two-tailed t-test.
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We graphically represented the uncertainty of these cost-effectiveness estimates in a cost-effectiveness
plane (Figure 15) using bootstrapping with 10,000 iterations. We sampled, at random with replacement,
each of our 10 imputed data sets, producing 10,000 incremental cost and incremental QALY estimates.
Figure 15 shows that all the points are above the x-axis, indicating that the volar locking plate was more
costly than K-wires, and more points are to the right of the y-axis, indicating that the volar locking plate
produced more QALYs than K-wires.
The points lay in the north-east quadrant of the cost-effectiveness plane. In this area there is a trade-off
between effect and cost: additional health benefit can be obtained but at a higher cost. The question that
then arises is whether or not the trade-off is acceptable, that is if the health gain is worth the additional
cost.48 This decision is based on the ICER and what the decision-makers are willing to pay for the
additional benefit. The guideline rule is the NICE threshold of £20,000–30,000 per QALY, and the ICER
of volar locking plates versus K-wires equals £89,322 per QALY. Under these circumstances, volar locking
plates cannot be considered cost-effective, as its ICER is above the £20,000–30,000 per QALY range.
The CEAC showing the probability that volar locking-plate fixation is cost-effective is presented in
Figure 16 with a range of cost-effectiveness WTP threshold values. The probability of being cost-effective
at a WTP threshold of £20,000 per QALYs was nil and at a threshold of £30,000 was 3%.
TABLE 33 Cost-effectiveness results (NHS perspective, all patients)
Treatment comparison Incremental cost (£) (95% CI) Incremental QALY gain (95% CI) ICER (£)
Volar locking plate vs. K-wires 726.46 (588.44 to 864.48) 0.008 (–0.001 to 0.018) 89,322
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FIGURE 15 Cost-effectiveness plane generated from bootstrapped mean cost and QALY differences over 12 months
(NHS perspective, all patients).
TABLE 32 Total costs and QALY gains by treatment arm (NHS perspective, all patients)
Parameter K-wires Volar locking plate
n 230 230a
Total QALY gain (SD) 0.734 (0.166) 0.742 (0.159)
Total cost (£) (SD) 3440.07 (2539.27) 4145.25 (2203.16)
a One patient was excluded from the health economic analysis as he did not complete the health economics questionnaire
at any follow-up point.
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Sensitivity analyses
We undertook a number of sensitivity analyses to test the robustness of the base-case results, which are
presented in Table 34.
The first sensitivity analysis was based on complete-case data. This resulted in an incremental cost of £903
and an incremental QALY gain of 0.014, yielding an ICER of £64,026 per QALY.
The sensitivity analyses also expanded the cost-effectiveness analysis to the societal perspective. The
incremental societal cost was £581 and the QALY gain was very comparable from the base-case analysis.
All the sensitivity analyses showed a higher mean cost and a higher but marginal QALY gain per patient
receiving a volar locking plate. The ICERs of volar locking-plate fixation compared with K-wires were
always more than £44,000 per QALY.
We also carried out cost-effectiveness analyses adjusting for the following baseline covariates including
age, gender and EQ-5D scores. The adjusted analysis on the multiple imputations showed a lower
incremental cost for a similar incremental QALYs gain both in the NHS and the societal perspectives;
however, both ICERs remained above the cost-effectiveness threshold of £30,000 per QALY.
Subgroup analyses
The same analysis was then undertaken for patients < 50 years of age and patients ≥ 50 years of age, as
the two age groups are assumed to present different types of fractures (high- and low-energy fractures)
and so the impact of the fixation is expected to differ by age.
Table 35 shows the total costs and QALY gains for each of the treatment arms in each subgroup.
Differences in QALY gains between groups were minimal in both age groups. The volar locking-plate
group had the highest QALY gains in patients aged ≥ 50 years and K-wires had the highest QALY
gains in younger patients. The mean total costs were higher for the volar locking-plate arm for both age
subgroups. Older patients showed higher total costs than younger patients.
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FIGURE 16 Cost-effectiveness acceptability curves at 12 months (NHS perspective, all patients).
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TABLE 35 Total costs and QALY gains by treatment arm (NHS perspective, all patients)
Parameter K-wires Volar locking plate
n 230 230
Patients aged ≥ 50 years
Total QALY gain (SD) 0.72 (0.14) 0.74 (0.13)
Total cost (£) (SD) 3759.9 (538.8) 3972.8 (464.4)
Patients aged < 50 years
Total QALY gain (SD) 0.77 (0.11) 0.75 (0.10)
Total cost (£) (SD) 2822.4 (499.9) 3218.6 (461.4)
TABLE 34 Sensitivity analyses
Sensitivity analysis Incremental cost (£) (95% CI) Incremental QALY gain (95% CI) ICER (£)
Unadjusted
Complete-case data
Volar locking plate vs. K-wires 903.41 (392.48 to 1414.34) 0.014 (–0.025 to 0.053) 64,026
LOCF imputed data
Volar locking plate vs. K-wires 799.17 (284.07 to 1314.27) 0.018 (–0.019 to 0.055) 44,468
Societal perspective: multiple imputed data
Volar locking plate vs. K-wires 581.00 (405.50 to 756.51) 0.010 (0.001 to 0.019) 58,852
Societal perspective: complete-case data
Volar locking plate vs. K-wires 790.45 (59.54 to 1521.36) 0.014 (–0.025 to 0.053) 56,020
Adjusted
Multiple imputations
Volar locking plate vs. K-wires 285.93 (171.41 to 400.44) 0.009 (–0.015 to 0.032) 32,730.50
Complete-case data
Volar locking plate vs. K-wires 907.44 (762.39 to 1052.50) 0.014 (–0.018 to 0.046) 64,662
LOCF imputed data
Volar locking plate vs. K-wires 799.17 (692.15 to 906.19) 0.018 (–0.012 to 0.048) 44,468
Societal perspective: multiple imputed data
Volar locking plate vs. K-wires 299.97 (157.68 to 442.26) 0.010 (–0.013 to 0.033) 30,385
Societal perspective: complete-case data
Volar locking plate vs. K-wires 791.85 (567.72 to 1015.99) 0.014 (–0.018 to 0.046) 56,425
LOCF imputed data
Volar locking plate vs. K-wires 799.17 (692.15 to 906.19) 0.018 (–0.012 to 0.048) 44,468
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Table 36 provides the cost-effectiveness results, showing the incremental costs and benefits as well as the
ICER. Interpretation should be tempered by considering the small between-group differences in QALY
gains and the high level of uncertainty surrounding the QALY estimates.
In the sample of patients aged ≥ 50 years, the evaluation suggests that patients treated with a volar
locking-plate fixation gained 0.014 QALYs more than those treated with a K-wire fixation, at an increased
cost of £752 per patient, yielding an ICER of £54,218 per QALY. Given a WTP of £20,000 for an additional
QALY, the probability of volar locking plates being cost-effective is 46% based on the trial data, as shown
in Figure 17.
In the sample of patients aged < 50 years, the evaluation suggests that volar locking-plate fixation
is associated with both lower benefits and higher costs than if they are treated with K-wires. The K-wire
fixation appears to dominate for this group of individuals.
Sensitivity analyses
We undertook a number of sensitivity analyses to test the robustness of the subgroup results, which are
presented in Table 37.
The results based on the complete cases are the same as the main analysis for patients aged ≥ 50 years,
showing an incremental QALY gain of approximately 0.02 and an incremental cost between £629 and
£945, yielding ICERs higher than £35,323 per QALY. With regard to younger patients, the QALY gain was
close to nil for patients aged < 50 years with an additional cost of £778, and K-wires would be a preferred
option for cost-minimisation reasons.
TABLE 36 Subgroups cost-effectiveness results
Parameter
Incremental cost (£)
(95% CI)
Incremental QALY gain
(95% CI) ICER (£ per QALY)
Patients aged ≥ 50 years
Volar locking plate vs. K-wires 752.45 (538.88 to 921.03) 0.014 (0.002 to 0.025) 54,218
Patients aged < 50 years
Volar locking plate vs. K-wires 652.81 (425.26 to 880.37) –0.008 (–0.024 to 0.008) –81,601 (K-wires dominates)
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FIGURE 17 Cost-effectiveness acceptability curves by age subgroups at 12 months (NHS perspective).
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Summary
The results showed that patients with distal radius fractures did not show differences in QALY gain
when treated with the volar locking-plate fixation or the K-wires. However, volar locking-plate fixation
presented positive incremental costs. This difference was driven by the higher cost of delivery of the volar
locking-plate fixation (£818.26 vs. £54.23); this cost was not offset through decreases in health-care
resource use during the 12-month follow-up after discharge. The incremental cost of volar locking-plate
fixation was £726 (95% CI £588.44 to £864.48) from an NHS perspective and £581 (95% CI £405.50 to
£756.51) from a societal perspective.
The base-case analysis based on imputed data found the incremental QALY gain to favour volar
locking-plate fixation; the difference was small (0.008; 95% CI –0.001 to 0.018). The limits of the CIs did
not include high QALY gain values where the study could have concluded that volar locking plates were
cost-effective; a back-of-the-envelope calculation indicates that a net QALY gain of at least 0.036 would
be required for the incremental cost of £726 to provide cost-effectiveness at a WTP of £30,000 per QALY.
The high ICER and the low probability of volar locking plates being cost-effective at a WTP between
£20,000 and £30,000 demonstrate that volar locking-plate fixation is not cost-effective. This result is
robust to sensitivity analysis and stochastic bootstrapping.
The subgroup analysis showed small fluctuations in effectiveness as measured in QALYs, differing with
patients’ age group (≥ or < 50 years old). The incremental QALY gain of volar locking plates in patients
aged ≥ 50 years was 0.014 (95% CI 0.002 to 0.025) whereas the incremental QALY gain of volar locking
plates in patients < 50 years was –0.008 (95% CI –0.024 to 0.008). The right-hand limit of the CIs for
QALY gains in younger patients shows that patients aged < 50 years are likely to experience an increased
quality of life with K-wires. As volar locking-plate fixation is always associated with higher incremental
costs than K-wires (£652.81; 95% CI £425.26 to £880.37), the evaluation suggests that K-wires fixation is
TABLE 37 Subgroups sensitivity analyses
Parameter
Incremental cost (£)
(95% CI)
Incremental QALY gain
(95% CI) ICER (£ per QALY)
Patients aged ≥ 50 years
Complete-case data
Volar locking plate vs. K-wires 944.93 (323.03 to 1566.83) 0.019 (–0.030 to 0.067) 50,959
LOCF imputed data
Volar locking plate vs. K-wires 858.60 (227.88 to 1489.32) 0.021 (–0.025 to 0.067) 41,018
Societal perspective: multiple imputed data
Volar locking plate vs. K-wires 628.57 (411.69 to 845.45) 0.018 (0.007 to 0.029) 35,323
Patients aged < 50 years
Complete-case data
Volar locking plate vs. K-wires 778.34 (–112.83 to 1669.52) 0.001 (–0.065 to 0.068) 590,973
LOCF imputed data
Volar locking plate vs. K-wires 621.14 (–221.54 to 1463.83) 0.007 (–0.051 to 0.066) 83,114
Societal perspective: multiple imputed data
Volar locking plate vs. K-wires 446.24 (172.32 to 720.15) –0.013 (–0.028 to 0.003) –34,326
(K-wires dominates)
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preferred in younger patients. For patients aged ≥ 50 years, the limits of the CIs did not include QALY
gain values higher than 0.018 and so volar locking-plate fixation is unlikely to be not cost-effective
(a back-of-the-envelope calculation indicates that a net QALY gain of at least 0.038 would be required for
the incremental cost of £752.50 to provide cost-effectiveness at a WTP of £30,000 per QALY).
The results showed that EQ-5D score was a suitable measure of health utility for this population and was
sensitive to distal radius fractures and fixation, as there were important changes in the score values over
the follow-up points.
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Chapter 5 Summary and discussion
Screening
Over 12,000 patients were screened during the course of the trial. There was a bimodal distribution.
The first peak was in younger men, although there was a smaller peak in women; both of these groups
most commonly suffer high-energy injuries associated with sport, etc. The second peak was predominantly
in women with lower-energy fractures most likely related to osteoporosis.
As expected, the most common reasons for patients being ineligible were ‘patient does not require
fixation’, ‘patient is age less than 18 years’ and ‘fracture > 3 cm from the radiocarpal joint’, that is the
fracture was not of the distal radius. These criteria accounted for the exclusion of roughly 10,000 patients.
The other ineligible patients were spread around the remaining eligibility criteria.
Of note, 430 patients with intra-articular fractures were excluded on the basis that the ‘surgeon needed
to open the fracture to achieve reduction of the joint surface’. Inevitably these fractures would be fixed
with a plate, since the incision required to reduce the joint surface is essentially the same as that required
for the insertion of the plate. There were 639 patients who fulfilled the eligibility criteria – some of whom
did not wish to take part in the trial for the reasons described – so the majority of the patients who met
the other eligibility criteria were considered by the surgeons to be eligible. Nonetheless, the number of
patients excluded from the analysis on the basis of the ‘surgeon needed to open the fracture to achieve
reduction of the joint surface’ eligibility criterion was perhaps greater than might have been expected
given the proportion of complex intra-articular fractures, that is those who might be expected to fulfil this
criteria, reported in the literature. Some surgeons may have taken a ‘cautious’ approach to the decision to
include a patient in the trial, that is they excluded the patient if there was any doubt about their ability
to subsequently reduce the joint surface without opening the joint. There was also some variability by
trial centre in the number of patients excluded for this reason, but this was not unexpected and reflects
variation in clinical practice and in particular the variation in surgeons’ willingness to open the joint surface.
To some degree, variation in the surgeons’ preoperative assessment of their ability to reduce the fracture
reflects such variation in clinical practice across the NHS.
Only a relatively small number of patients (n= 116) were excluded as being ‘unable to adhere to
trial procedures or complete questionnaires’. This most likely reflects the fact that the questionnaires were
completed by post and hence patients with no fixed address could not take part, and also that translation
services could not be provided for patients whose first language was not English.
Declined to participate
Only 178 potentially eligible patients (28%) declined to take part. This is reassuring in terms of the
trial paperwork and in particular the state of equipoise presented in the patient information sheet,
but also in terms of the generalisability of the trial to the broader population. The most common reason
(55 patients, 31% of those who declined to participate) was the ‘patient did not want to take part in a
research project’.
Importantly, the number of patients declining to take part because they had a strong preference for one
intervention was both small and equally divided between the treatment arms: 26 patients (15%) ‘definitely
wants K-wires’ and 29 patients (16%) ‘definitely wants plate’. Therefore, patients had equipoise and
patient preference should not have influenced the result of the trial.
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Treatment according to allocation
This was clearly an important issue because either surgeon or patient preference could have led to
crossover from one group to the other post randomisation. However, > 90% of both patient groups had
their allocated treatment according to protocol, 208 out of 231 patients allocated to K-wires (90%) and
213 out of 230 patients allocated to locking plates (92%). This ensured that the primary intention-to-treat
analysis was not different from the planned secondary per-treatment analysis. Interestingly, in the case
of nine patients, the surgeon decided not to use either form of fixation, that is the patient had a
manipulation under anaesthetic and application of plaster cast without ‘metalwork’.
Recruitment by centre
Each of the 18 centres successfully recruited to the trial. As expected, the centres that opened earliest in
the trial recruited the most patients overall. Most centres achieved a recruitment rate of 1–2 patients
per month, indicating that the pre-trial recruitment rate estimate was accurate.
The lead centre recruited the most patients, as may be expected. However, there was also a noticeable
difference in the rate of recruitment in some other centres. This may reflect the size of the catchment
area (number of patients seen) at that centre or the amount of snow and ice, and hence falls, in that area,
for example Newcastle and North Tyneside, but may also reflect a different ‘clinical threshold’ for offering
patients surgery following a fracture of the distal radius. This warrants further investigation.
Baseline characteristics of the two groups
The two groups were ‘beautifully balanced in terms of baseline characteristics’ (quote from the
trial statistician).
In particular, the stratification by age, as a surrogate for bone density, and by intra-articular extension led
to a good balance of these characteristics between treatment groups.
Patients
There were slightly more fractures of the left wrist than the right, but these were also evenly balanced
between treatment groups, as were injuries to the ‘dominant hand’. This may reflect the fact that people
generally carry things in their dominant hand, and, therefore, may be more likely to put out their
non-dominant hand if they fall.
The number of patients with ‘pre-existing wrist problems’ was low (14% K-wires, 17% locking plates) and
this was reflected in the pre-injury wrist scores, which were near ‘normal’ in both groups (PRWE
questionnaire 3/100, where 0 is the best score).
As expected, the most common mechanism of injury was ‘low-energy fall’ at 82% in the K-wire group
and 83% in the locking-plate group. All other patient characteristics were also evenly balanced
between groups.
Fractures
As expected, the great majority of fractures were either displaced extra-articular (AO type A) or complete
articular (AO type C) fractures. Partial articular (AO type B) fractures are most commonly palmar
fractures or styloid fractures and would, therefore, not be eligible for this trial of dorsally displaced fractures
of the distal radius. The type of fracture was evenly distributed between groups.
The other feature of note is that the proportion of AO type C3 fractures – the most severe intra-articular
fractures – was low in both groups. This was also expected as these are the fractures where the
surgeon would most commonly need ‘to open the fracture site to achieve reduction of the articular
surface’ and were also, therefore, not eligible for the trial.
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Surgeons
In this pragmatic trial, we expected that a large number of surgeons, reflecting the true breadth of
expertise and experience provided within the NHS, would deliver the trial interventions. This was indeed
the case, with 244 surgeons delivering a median of one operation each. This greatly reduces the likelihood
of a surgeon-specific effect on the outcome at any one centre, that is one particularly good or bad
surgeon dominating the other surgeons in the study.
However, it was also important to look at the balance of surgeons delivering the two different interventions.
Interestingly, this was also well balanced between the groups.
Before the trial, some senior surgeons may have considered the K-wire intervention ‘simpler’ and therefore
allowed more junior colleagues to perform this operation while the more experienced surgeons performed
the more ‘complicated’ locking-plate fixation. This may have led to a ‘surgeon-effect’ within the trial.
However, only marginally more of the plate fixations were performed by consultant (attending) surgeons:
31% for locking plates compared with 26% for K-wires. Similarly, the surgeon’s experience, as defined
by the number of operations performed previously, was also well balanced between the groups. Therefore,
a surgeon effect is very unlikely.
Just under half of the procedures in both groups (44% K-wires, 46% locking plates) were performed by
‘specialist registrars’, that is, trainees under supervision, which again reflects the reality of the delivery
of trauma care in the NHS and is a testament to good training in this area.
Surgery
Although the principles of the fixation are inherent in the technique for both K-wires and locking plates,
the details of the surgery were left to the discretion of the treating surgeon in this pragmatic trial.
Wires
As per traditional training, the great majority of wire fixations involved two or three wires. The
most common size of wire used was 1.6mm. The most common mode of insertion (34%) was
‘inter-fragmentary’, that is the wire was passed through the distal bone fragment and into the proximal.
Twenty-four per cent of surgeons used the Kapandji technique alone, where the wire is inserted into the
fracture site rather than the distal fragment and used as a buttress to hold the position of the bone.
The remaining surgeries used a mixed technique, which may reflect a more recent trend.
Plates
The number of fixed-angle screws used in the distal bone fragment was variable but the largest single
number used was ‘> 5’ in 38% of surgeries. This is in keeping with the use of modern locking-plate
systems, which provide multiple options for gaining fixation in the distal metaphyseal bone, particularly
in intra-articular fractures. Surgeons may have chosen to use fewer distal locking screws in the
extra-articular fractures.
The bone in the proximal part of the radius is much thicker ‘cortical’ bone, such that traditional
‘non-locking’ screws are thought to achieve adequate fixation in this area. However, locking screws were
also used in the proximal fragment in nearly half (44%) of the surgeries. This variation in practice has
cost implications, as the locking screws are generally more expensive.
Duration of surgery
A key finding of this trial is that the K-wire surgery took less than half the time of the locking-plate
fixation, 31 minutes (24 to 45 minutes) for K-wires compared with 66 minutes (50 to 85 minutes) for
locking plates. There was no evidence that there was a difference in the duration of surgery according to
the seniority of the lead surgeon.
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As access to trauma operating theatre space is a key limiting factor in the delivery of trauma care across
the NHS, and indeed has secondary effects on the delivery of elective (planned) surgery as well, this finding
is of particular importance to policy-makers and NHS managers. It also has financial implications,
as theatre operating time is an expensive resource. However, it is difficult to ‘cost’ this time accurately, as
many of the costs of theatre time – staff, cleaning, maintenance – are present even if the theatre is not
being used at 100% capacity. Theatre time was, therefore, not included in the health economics analysis,
which may have led to some underestimation of the cost-effectiveness of K-wire fixation.
Follow-up rate
The follow-up rate was excellent, with 90% complete follow-up at each time point in both groups of
patients. This suggests that the follow-up protocol was satisfactory, and also contributes to the external
validity of the trial.
Outcomes
Primary outcome
The main finding of this trial is that there is no difference in the primary outcome PRWE questionnaire
score at 3 months, 6 months or 12 months (difference in PRWE questionnaire score at 12 months
–1.3, 95% CI –4.5 to 1.8; p= 0.398) between patients treated with K-wire fixation versus
locking-plate fixation.
As the CIs exclude the MCID for the PRWE questionnaire, we conclude that any difference in functional
scores between treatment groups is unlikely to be important to patients.
The size of the treatment effect seen in this trial is consistent with that seen in other studies of recovery
following fracture of the distal radius. MacDermid et al.30 conducted a prospective cohort study of
129 patients with a fracture of the distal radius; all patients completed the PRWE questionnaire at their
baseline clinic visit and at 2 months, 3 months, 6 months and 12 months following their fracture. They
reported a mean PRWE questionnaire score of 20.0 (SD 20.6) at 6 months and a score of 13.5 (SD 17.0)
at 12 months. This is consistent with our reported values of 21.5 (SD 18.1) and 14.6 (SD 16.4) for the full
population at 6 months and 12 months postoperatively.
Secondary outcomes
Patient-reported secondary outcomes
Furthermore, secondary clinical outcomes show that there is no difference between the groups in
terms of health-related quality of life or the risk of complications. There was a borderline significant
difference in the DASH questionnaire at one time point in favour of the locking plate, but this was well
below the MCID.49
Complications
There was no evidence to suggest that rates for any of the reported complications (e.g. wound infections)
differed between treatment groups, based on comparing counts in groups. The number of complications
was fortunately small and, again, it is important to note that the trial was not powered to look for
differences in complications per se.
Although it is unlikely that there is a major difference in the overall rate of complications between K-wire
fixation and locking-plate fixation, there may still be differences in the individual complications. This
intuitively makes sense. One might expect the rate of superficial infection to be higher in the wire group
(18 cases) versus the locking-plate group (12 cases), as the wires are generally applied directly through
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the skin, which is colonised by bacteria. Similarly, the number of neurological injuries in the locking-plate
group (20 cases) versus the K-wire group (14 cases) may also be expected, since the plates require a
surgical approach to the bone close to the major nerves of the wrist.
In terms of the requirement for further surgery, there was also little difference between the groups.
Five patients in the K-wire group and two in the locking-plate group required revision surgery for loss of
reduction, that is the bone was not held in an acceptable position during healing, as determined by
the treating surgeon, whereas nine patients in the plate group required removal of symptomatic
metalwork (four for screw penetration of the joint) and one patient had a buried K-wire which also
required removal in theatre.
Radiographic results
Dorsal angle (°) and ulnar variance (mm) data were extracted from available images from all study
participants before their operation, and at 6 weeks and 12 months after their surgery. The dorsal angle
is a measurement of how far the articulating surface of the distal radius is tilted away from the palm
by the injury; a normal articular surface faces towards the palm by a few degrees. Ulnar variance is a
measurement of how far the radius has shortened relative to the ulna; in the uninjured wrist they are
usually the same length. The 6-week images were used to determine whether or not the initial reduction
of the fracture was maintained, that is if the bone was held in the anatomical position by the fixation
device. The 12-month images were used to look for ‘late collapse’ of the fracture, as discussed in
the protocol.
Agreement between independent assessors (one radiologist and one orthopaedic surgeon), as determined
by intraclass correlation, was above 0.8 for both measurements at each time point. This ‘near perfect’
agreement suggests that the measurements were reproducible, even if there was some error in
individual measurements.
In terms of dorsal angulation, there was a mean 3° difference in the angulation in favour of the locking-plate
group at 6 weeks. Similarly, there was a mean 0.75mm less shortening of the radius in the locking-plate group.
These results are statistically significant. As noted in the introduction, most previous trials have suggested
that locking-plate fixation provides improved radiographic outcomes, possibly because they can be used
to aid the reduction of the bones into the correct (anatomic) position as well as holding that position
when screwed to the bone surface. K-wires usually require the bone fragments to be reduced before the
wires are inserted. However, the clinical relevance of such small differences is questionable. The long-term
follow-up of the patients will hopefully provide some indication of whether or not radiographic
measurements have a bearing on long-term clinical outcome.
At 12 months, the differences between the treatment groups persisted. The mean dorsal tilt in the
wire group increased by 0.67° and the shortening by 0.33mm between 6 weeks and 12 months.
Therefore, ‘late collapse’ was minimal. This does not mean that late collapse did not occur in an individual
patient but, on average, it was very unlikely to be clinically important.
It is difficult to explain why the mean dorsal tilt in the locking-plate group actually improved by 0.9°
between 6 weeks and 12 months, other than measurement error.
Pre-planned subgroup and secondary analyses
At the beginning of the trial, three variables were identified as being of potential importance in terms of
their influence on the recovery of patients following fracture of the distal radius. The randomisation
sequence was therefore stratified on the basis of trial centre/hospital, age above and below 50 years as a
surrogate for osteoporosis, and intra-articular extension of the fracture into the radiocarpal joint.
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A single random effect was used to take account of the trial centre in the regression model used in the
adjusted analysis; this made very little difference to the mean difference in PRWE questionnaire score
between the groups (all participants: –1.3 adjusted, –1.4 raw).
The trial was not powered specifically for subgroup analysis. However, as three-quarters (314 out of 461)
of the patients were in the ‘over 50 years’ subgroup, the estimate of the mean difference at 12 months
is reasonably precise. The adjusted estimate of the mean difference between the treatments for the ‘over
50 subgroup’ is –2.2 points in favour of the plate fixation, but as the CIs exclude the MCID of 6 points
on the PRWE questionnaire score (95% CI –5.8 to 1.4) this is unlikely to be clinically relevant.
The adjusted analysis for the ‘under 50 years’ subgroup was 1.4 in favour of the K-wire fixation.
As the number of patients in this subgroup was smaller, the CIs are broader and do include the MCID
(95% CI –5.0 to 7.8).
The number of patients analysed at 12 months with an intra-articular extension of the fracture (n= 200)
was similar to those without (n= 215). Again, there was no evidence of a difference between the
treatment groups. The mean difference was 0.7 (–3.8 to 5.2) for those patients with an intra-articular
extension and –3.3 (–7.6 to 1.1) for those without.
Therefore, this trial provided no evidence of a clinically important difference between the effect of K-wire
fixation and that of locking-plate fixation for patients under or over 50 years or for patients with and
without an intra-articular extension of their distal radius fracture.
Finally, we also pre-planned a per-treatment (per protocol) secondary analysis of the data. As compliance
with the trial was good, with > 90% of patients receiving their allocated treatment, the analysis by
treatment given did not alter the result.
Health economic evaluation
Costs of initial surgery
The costs of the initial surgical interventions were markedly different; the total cost of the implants and
theatre consumables was £54 for the K-wire fixation versus £818 for the locking-plate fixation. Therefore,
K-wire fixation is a cost-saving intervention.
As noted above, this is a conservative estimate of the cost of initial surgery, as this does not take into
account the extra theatre operating time required for the locking-plate fixation, which was 31 minutes for
K-wires and 6 minutes for locking plates.
Other health resource use
The use of other health resource was broadly comparable between the treatment groups, as £1525 for
K-wires and £1590 for volar locking plates. There was no statistically significant difference in the use
of any individual service, orthotic or medication.
Both groups of patients were frequent users of physiotherapy services (seven visits over the 12 months)
and reported on average 3.6 radiology visits for radiographs and 3.6 visits to the orthopaedic outpatient
department. Use of GP visits and nurse visits was infrequent.
Societal costs
Cost from the societal perspective were calculated by combining productivity loss and loss of earnings
due to work absence, private costs such as treatments within private settings and out-of-pocket
expenses incurred as a result of the wrist surgery, and reported use of personal social services related
to the treatment.
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Again, there was very little difference between the treatment groups; overall societal costs were on
average £70 higher for the patients having K-wire fixation.
Cost-effectiveness
There were no significant differences in health-related quality of life during the 12-month follow-up period
and hence very little difference in average total QALY between the two groups: 0.08 difference, volar
locking plate 0.745 versus K-wire 0.731.
As the locking-plate intervention was more expensive, with a total incremental cost of £726, the ICER of
volar locking plates versus K-wires was £89,322 per QALY. Under these circumstances, volar locking
plates cannot be considered cost-effective. The probability of being cost-effective at a WTP threshold of
£20,000 per QALYs was nil and at a threshold of £30,000 was 3%.
Cost-effectiveness in pre-planned subgroups
There were small differences in QALY depending on the patients’ age group. Therefore, there were small
differences in cost-effectiveness according to age.
As patients aged < 50 years were likely to experience a marginal increase in quality of life with the cheaper
K-wires, the health economic evaluation suggests that K-wire fixation is always preferred in
younger patients.
In patients aged ≥ 50 years, there was a marginal increase in the unadjusted QALY gain with locking-plate
fixation. Given a WTP for an additional QALY of £20,000, the probability of locking-plate fixation being
cost-effective is 46% based on the trial data. Therefore, it is unlikely that locking-plate fixation would
be cost-effective in older patients.
Limitations
The main limitation of the trial is that it was not possible to blind either the surgeons or the patients to the
study treatments. However, it could be argued that this is a positive feature in a pragmatic trial, as patients
would know about their proposed treatment before surgery during routine care.50
It should be noted that this study excluded patients whose fracture could not be reduced by indirect
means, that is the results should not be generalised to the minority of patients whose fracture requires
that the surgeon expose the individual bone fragments in order to restore the congruity of the wrist joint.
The low number of patients in the trial with C3 fractures indicates that, as expected, the patients with
the most complex intra-articular fractures were the ones who were excluded. None of the patients with
extra-articular fractures should have been excluded, as this eligibility criterion refers only to the reduction
of the ‘joint surface’. While it is possible that a small number of patients were excluded in error, we think
this unlikely given the high quality of the screening data which we collected throughout the trial.
Of course, we have no way of checking the radiographs of those patients whom the surgeon considered
to be ineligible, but variation in the interpretation of fractures and fracture patterns is inherent in clinical
practice and is reflected in this trial.
Compliance with the trial was good, with > 90% of patients receiving their allocated treatment. Some
patients did cross over to have a different form of fixation, but an analysis by treatment given did not alter
the result.
It is also important to underline that the health economics analysis used a conservative estimate of the
cost of initial surgery. This did not take into account the extra theatre operating time required for the
locking-plate fixation at 31 minutes for K-wires and 66 minutes for locking plates. It is likely that a
microcosting analysis of the initial surgery in each arm could lead to even higher cost differences with
regard to the cost of the initial surgery.
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The long-term outcome of patients with a fracture of the distal radius is not known. Our data suggest that
patients’ wrist function and quality of life improve over the 12 months following their surgery but do not
return to pre-injury levels. The patients in this trial will be followed up annually, to determine the
prevalence of late complications such as arthritis. In addition, this will provide us with data on the longer
term that will allow a decision-analytic model where extrapolation will rely on more robust data on
the benefits.
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Chapter 6 Conclusion
This trial found no clinically relevant difference in PRWE questionnaire results in the 12 months followingK-wire fixation versus volar locking-plate fixation. The health economic evaluation showed that K-wire
fixation is cost saving.
The results of this trial will reverse the trend towards locking-plate fixation for this injury, and will,
consequently, save time and money for health-care services around the world.
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Appendix 2 Patient information sheet
DOI: 10.3310/hta19170 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 17
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87

Appendix 3 Background information
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Appendix 4 Baseline questionnaire
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Appendix 5 Randomisation form
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Appendix 6 Operation note
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Appendix 7 Six-week follow-up clinic
DOI: 10.3310/hta19170 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 17
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
Appendix 8 Example follow-up questionnaire
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Appendix 9 Serious adverse event form
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